Transplantation of an individual's own tissue from one site to another site.
The transference of a part of or an entire liver from one human or animal to another.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
The transference of a kidney from one human or animal to another.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
The transference of a heart from one human or animal to another.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
The transference of either one or both of the lungs from one human or animal to another.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
Transference of an organ between individuals of the same species or between individuals of different species.
Reinfusion of blood or blood products derived from the patient's own circulation. (Dorland, 27th ed)
An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.
Transference of cells within an individual, between individuals of the same species, or between individuals of different species.
The transference of a pancreas from one human or animal to another.
The transference of pancreatic islets within an individual, between individuals of the same species, or between individuals of different species.
Individuals supplying living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients.
A general term for the complex phenomena involved in allo- and xenograft rejection by a host and graft vs host reaction. Although the reactions involved in transplantation immunology are primarily thymus-dependent phenomena of cellular immunity, humoral factors also play a part in late rejection.
Transference of a tissue or organ from either an alive or deceased donor, within an individual, between individuals of the same species, or between individuals of different species.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
An organism that, as a result of transplantation of donor tissue or cells, consists of two or more cell lines descended from at least two zygotes. This state may result in the induction of donor-specific TRANSPLANTATION TOLERANCE.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
Transplantation between genetically identical individuals, i.e., members of the same species with identical histocompatibility antigens, such as monozygotic twins, members of the same inbred strain, or members of a hybrid population produced by crossing certain inbred strains.
Non-cadaveric providers of organs for transplant to related or non-related recipients.
Transplantation of tissue typical of one area to a different recipient site. The tissue may be autologous, heterologous, or homologous.
Transplantation of STEM CELLS collected from the fetal blood remaining in the UMBILICAL CORD and the PLACENTA after delivery. Included are the HEMATOPOIETIC STEM CELLS.
Elements of limited time intervals, contributing to particular results or situations.
The simultaneous, or near simultaneous, transference of heart and lungs from one human or animal to another.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
The return of a sign, symptom, or disease after a remission.
Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.
An induced state of non-reactivity to grafted tissue from a donor organism that would ordinarily trigger a cell-mediated or humoral immune response.
The administrative procedures involved with acquiring TISSUES or organs for TRANSPLANTATION through various programs, systems, or organizations. These procedures include obtaining consent from TISSUE DONORS and arranging for transportation of donated tissues and organs, after TISSUE HARVESTING, to HOSPITALS for processing and transplantation.
Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed)
Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.
The grafting of skin in humans or animals from one site to another to replace a lost portion of the body surface skin.
Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)
Transference of fetal tissue between individuals of the same species or between individuals of different species.
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
Transfer of MESENCHYMAL STEM CELLS between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS).
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Transplantation between animals of different species.
Transference of tissue within an individual, between individuals of the same species, or between individuals of different species.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Therapeutic act or process that initiates a response to a complete or partial remission level.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Prospective patient listings for appointments or treatments.
The degree of antigenic similarity between the tissues of different individuals, which determines the acceptance or rejection of allografts.
Partial or total replacement of the CORNEA from one human or animal to another.
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.
A dead body, usually a human body.
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Progenitor cells from which all blood cells derive.
The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Transference of brain tissue, either from a fetus or from a born individual, between individuals of the same species or between individuals of different species.
Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.
Pathological processes of the LIVER.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
The transference between individuals of the entire face or major facial structures. In addition to the skin and cartilaginous tissue (CARTILAGE), it may include muscle and bone as well.
The process by which organs are kept viable outside of the organism from which they were removed (i.e., kept from decay by means of a chemical agent, cooling, or a fluid substitute that mimics the natural state within the organism).
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
The procedure established to evaluate the health status and risk factors of the potential DONORS of biological materials. Donors are selected based on the principles that their health will not be compromised in the process, and the donated materials, such as TISSUES or organs, are safe for reuse in the recipients.
Organs, tissues, or cells taken from the body for grafting into another area of the same body or into another individual.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Disease having a short and relatively severe course.
Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Measure of histocompatibility at the HL-A locus. Peripheral blood lymphocytes from two individuals are mixed together in tissue culture for several days. Lymphocytes from incompatible individuals will stimulate each other to proliferate significantly (measured by tritiated thymidine uptake) whereas those from compatible individuals will not. In the one-way MLC test, the lymphocytes from one of the individuals are inactivated (usually by treatment with MITOMYCIN or radiation) thereby allowing only the untreated remaining population of cells to proliferate in response to foreign histocompatibility antigens.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
The procedure of removing TISSUES, organs, or specimens from DONORS for reuse, such as TRANSPLANTATION.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Inflammation of the BRONCHIOLES leading to an obstructive lung disease. Bronchioles are characterized by fibrous granulation tissue with bronchial exudates in the lumens. Clinical features include a nonproductive cough and DYSPNEA.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
The period following a surgical operation.
Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.
The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
Antibodies produced by a single clone of cells.
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
The transfer of lymphocytes from a donor to a recipient or reinfusion to the donor.
The transference of a complete HAND, as a composite of many tissue types, from one individual to another.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
An antigenic mismatch between donor and recipient blood. Antibodies present in the recipient's serum may be directed against antigens in the donor product. Such a mismatch may result in a transfusion reaction in which, for example, donor blood is hemolyzed. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984).
An antibiotic substance derived from Penicillium stoloniferum, and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1301)
Criteria and standards used for the determination of the appropriateness of the inclusion of patients with specific conditions in proposed treatment plans and the criteria used for the inclusion of subjects in various clinical trials and other research protocols.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
A general term for various neoplastic diseases of the lymphoid tissue.
Immunological rejection of tumor tissue/cells following bone marrow transplantation.
Final stage of a liver disease when the liver failure is irreversible and LIVER TRANSPLANTATION is needed.
Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
The grafting of bone from a donor site to a recipient site.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
The preparation of leukocyte concentrates with the return of red cells and leukocyte-poor plasma to the donor.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
Non-human animals, selected because of specific characteristics, for use in experimental research, teaching, or testing.
Disorders of the blood and blood forming tissues.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
A state of prolonged irreversible cessation of all brain activity, including lower brain stem function with the complete absence of voluntary movements, responses to stimuli, brain stem reflexes, and spontaneous respirations. Reversible conditions which mimic this clinical state (e.g., sedative overdose, hypothermia, etc.) are excluded prior to making the determination of brain death. (From Adams et al., Principles of Neurology, 6th ed, pp348-9)
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.
Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).
The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with MOSAICISM in which the different cell populations are derived from a single individual.
The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed)
A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.
Immunological rejection of leukemia cells following bone marrow transplantation.
Methods for maintaining or growing CELLS in vitro.
Surgical union or shunt between ducts, tubes or vessels. It may be end-to-end, end-to-side, side-to-end, or side-to-side.
The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
A form of ischemia-reperfusion injury occurring in the early period following transplantation. Significant pathophysiological changes in MITOCHONDRIA are the main cause of the dysfunction. It is most often seen in the transplanted lung, liver, or kidney and can lead to GRAFT REJECTION.
Antibodies from an individual that react with ISOANTIGENS of another individual of the same species.
A short thick vein formed by union of the superior mesenteric vein and the splenic vein.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
The physiological renewal, repair, or replacement of tissue.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Bone-marrow-derived, non-hematopoietic cells that support HEMATOPOETIC STEM CELLS. They have also been isolated from other organs and tissues such as UMBILICAL CORD BLOOD, umbilical vein subendothelium, and WHARTON JELLY. These cells are considered to be a source of multipotent stem cells because they include subpopulations of mesenchymal stem cells.
General dysfunction of an organ occurring immediately following its transplantation. The term most frequently refers to renal dysfunction following KIDNEY TRANSPLANTATION.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery.
Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by species members who lack it, an immune response is induced. Typical isoantigens are the BLOOD GROUP ANTIGENS.
Tumors or cancer of the LIVER.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
Preservation of cells, tissues, organs, or embryos by freezing. In histological preparations, cryopreservation or cryofixation is used to maintain the existing form, structure, and chemical composition of all the constituent elements of the specimens.
The period of care beginning when the patient is removed from surgery and aimed at meeting the patient's psychological and physical needs directly after surgery. (From Dictionary of Health Services Management, 2d ed)
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
Progressive destruction or the absence of all or part of the extrahepatic BILE DUCTS, resulting in the complete obstruction of BILE flow. Usually, biliary atresia is found in infants and accounts for one third of the neonatal cholestatic JAUNDICE.
A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.
Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
A repeat operation for the same condition in the same patient due to disease progression or recurrence, or as followup to failed previous surgery.
The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.
Therapies that involve the TRANSPLANTATION of CELLS or TISSUES developed for the purpose of restoring the function of diseased or dysfunctional cells or tissues.
The chilling of a tissue or organ during decreased BLOOD perfusion or in the absence of blood supply. Cold ischemia time during ORGAN TRANSPLANTATION begins when the organ is cooled with a cold perfusion solution after ORGAN PROCUREMENT surgery, and ends after the tissue reaches physiological temperature during implantation procedures.
Any procedure in which blood is withdrawn from a donor, a portion is separated and retained and the remainder is returned to the donor.
A cytologic technique for measuring the functional capacity of stem cells by assaying their activity.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
Generating tissue in vitro for clinical applications, such as replacing wounded tissues or impaired organs. The use of TISSUE SCAFFOLDING enables the generation of complex multi-layered tissues and tissue structures.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
Excision of all or part of the liver. (Dorland, 28th ed)
The number of PLATELETS per unit volume in a sample of venous BLOOD.
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
An individual that contains cell populations derived from different zygotes.
A technique of culturing mixed cell types in vitro to allow their synergistic or antagonistic interactions, such as on CELL DIFFERENTIATION or APOPTOSIS. Coculture can be of different types of cells, tissues, or organs from normal or disease states.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells.
The transfer of blood platelets from a donor to a recipient or reinfusion to the donor.
Persons or animals having at least one parent in common. (American College Dictionary, 3d ed)
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
An immunological attack mounted by a graft against the host because of tissue incompatibility when immunologically competent cells are transplanted to an immunologically incompetent host; the resulting clinical picture is that of GRAFT VS HOST DISEASE.
An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)

Natural history of papillary lesions of the urinary bladder in schistosomiasis. (1/3859)

Variable epithelial hyperplasia was observed in urinary bladder of nine capuchin monkeys (Cebus apella) when examined at cystotomy 94 to 164 weeks after infection with Schistosoma haematobium. These hosts were followed for 24 to 136 weeks postcystotomy to determine the status of bladder lesions in relation to duration of infection and to ascertain whether lesion samples removed at cystotomy reestablished themselves in autologous and heterologous transfers. There was involution of urothelial hyperplasia in eight of nine animals and no evidence for establishment of transplanted bladder lesions.  (+info)

Autografting with philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. (2/3859)

Intensive chemotherapy given in early chronic phase of chronic myelogenous leukemia (CML) has resulted in high numbers of circulating Philadelphia (Ph) chromosome-negative hematopoietic progenitor cells (HPC). We have autografted 30 consecutive patients with CML in chronic phase with HPC collected in this way to facilitate restoration of Ph-negative hematopoiesis in bone marrow after high-dose therapy. Hematopoietic recovery to greater than 0.5 x10(9)/L neutrophils and to greater than 25 x 10(9)/L platelets occurred in all patients, a median of 13 (range, 9 to 32) days and 16 (range, 6 to 106) days postautograft, respectively. Regenerating marrow cells were Ph-negative in 16 (53%) patients and greater than 66% Ph-negative in 10 (33%) patients. Twenty-eight patients are alive 6 to 76 months (median, 24 months) after autografting. Three patients have developed blast crisis from which 2 have died. Eight patients are in complete cytogenetic remission at a median of 20 (range, 6 to 44) months with a median ratio BCR-ABL/ABL of 0.002 (range, <0.001 to 0.01). Eight patients are in major cytogenetic remission at a median of 22 (range, 6 to 48) months. No patient died as a consequence of the treatment. All patients had some degree of stomatitis that was severe in 15 (50%) patients. Gastrointestinal and hepatic toxicities were observed in about one fourth of patients. Thus, autografting with Ph-negative mobilized HPC can result in prolonged restoration of Ph-negative hematopoiesis for some patients with CML; moreover, most autograft recipients report normal or near normal activity levels, suggesting that this procedure need not to be associated either with prolonged convalescence or with chronic debility.  (+info)

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. (3/3859)

We analysed 57 patients with non-myeloid malignancies who received a non-purged autologous PBSCT. All had similar mobilisation and conditioning regimens. A high prior chemotherapy score and the number of chemotherapy lines used (P = 0.015 and P = 0.01, respectively) were adverse predictors of CD34 cell yields. Lower CD34 values (P = 0.002) were seen in patients treated with potent stem cell toxins (BCNU, melphalan, CCNU and mustine), designated toxicity factor 4 agents (TF4). All patients infused with grafts containing CD34 cell doses between 1.0 and 2.0 x 10(6)/kg (range 1.25-1.90) engrafted by day 51. The only variable associated with slow platelet recovery was exposure to TF4 (P = 0.007). The majority of patients with CD34 >1.0 x 10(6)/kg achieved rapid and sustained engraftment and the only predictive factor of delayed recovery is prior exposure to stem cell toxins. Potential PBSCT candidates should if possible avoid first line and salvage chemotherapy containing TF4 drugs. We therefore advocate a minimum CD34 threshold of >1.0 x 10(6)/kg in patients without extensive prior chemoradiotherapy, and > or = 2.0 x 10(6)/kg in all other patients.  (+info)

Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. (4/3859)

The effect of an extensive prophylactic antimicrobial regimen was prospectively assessed in 126 patients after high-dose chemotherapy and autologous PBSC. They received ciprofloxacin (500 mg/12 h), acyclovir (200 mg/6 h), and itraconazole (200 mg/12 h) orally until neutrophil recovery. Febrile patients received i.v. imipenem (500 mg/6 h) to which vancomycin and amikacin were added if fever persisted for 2-3 and 5 days, respectively. Amphotericin B lipid complex was further given on day 7 or 8 of fever. Median times for a neutrophil count of >0.5 x 10(9)/l and a platelet count of >20 x 10(9)/l were 9 and 11 days. Severe neutropenia (<0.1 x 10(9)/l) lasted for a median of 5 days in which 72% of febrile episodes and 50% of cases of bacteremia occurred. Gram-positive bacteria were isolated in 30 of 40 episodes of bacteremia, 25 of which were caused by Staphylococcus epidermidis. Clinical foci were the intravascular catheter in 35 cases, respiratory infection in 11, cellulitis in two, anal abscess in one, and neutropenic enterocolitis in one. The high incidence of febrile episodes (94%) and bacteremias (31%) may be due to the lack of efficacy of antimicrobial prophylaxis and the persistence of a 5-day period of severe neutropenia.  (+info)

Lymphomatoid granulomatosis following autologous stem cell transplantation. (5/3859)

Lymphomatoid granulomatosis (LYG) is a rare angio-destructive lymphoproliferative disorder (LPD) of uncertain etiology, with prominent pulmonary involvement. Recent studies indicate that LYG is an Epstein-Barr virus (EBV)-associated B cell LPD with large numbers of background reactive T lymphocytes (T cell-rich B cell lymphoma). Although the disease frequently, but not exclusively, occurs in various immunodeficiency states, it has not been reported in association with the transient immunosuppression following autologous bone marrow/peripheral stem cell transplantation (ABM/PSCT). We describe a patient who developed lymphomatoid granulomatosis of the lung approximately 2 weeks after high-dose chemotherapy and autologous peripheral stem cell transplantation for multiple myeloma. Although molecular studies showed no evidence of EBV genome in the biopsy material, the serologic profile with high IgM titers was suggestive of primary EBV infection. Complete radiologic remission occurred following reconstitution of the patient's immune response after a 2-week course of ganciclovir treatment. Despite the apparently low frequency of LPD (both LYG and EBV-associated post-transplant lymphoma) in the ABMT setting, we believe that it should be considered in the differential diagnosis of patients whose clinical course following ABMT is complicated by fevers, in the absence of an identifiable infectious process.  (+info)

Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. (6/3859)

A limited number of patients with adult T cell leukemia/lymphoma (ATL) who received autologous stem cell transplantation (ASCT) have been reported. We report here a case of fatal systemic Candida krusei infection in a female patient with ATL undergoing ASCT. All of the eight patients (including seven patients in the literature) with ATL who received ASCT developed relapse of ATL or death due to ASCT complication, irrespective of subtype or remission state of ATL, source or selection of SCT or conditioning regimen. At present, ASCT appears to provide little benefit for ATL in contrast to that for other types of aggressive non-Hodgkin's lymphoma.  (+info)

Rapid autologous marrow recovery and eradication of infectious mononucleosis despite severe immunosuppression following second transplantation for aplastic anemia. (7/3859)

A patient with aplastic anemia failed to respond to immunosuppressive therapy and first marrow transplantation (BMT). Recovery of autologous hematopoiesis was rapid following a second stem cell transplant with a non-myeloablative preparatory regimen. The autologous immune response to infectious mononucleosis (IM) 4 weeks post-transplant was normal despite recent and ongoing severe immunosuppression.  (+info)

Advances in therapy of multiple myeloma: lessons from acute leukemia. (8/3859)

This paper traces the lack of progress, until recently, in the treatment of multiple myeloma (MM) to having ignored the principles that led to cure in acute leukemia more than 2 decades ago. Only in the mid-1980s did investigation begin to consider complete remission (CR) a research objective, representing a necessary first step toward cure. The experience with autologous and allogeneic stem cell-supported high-dose therapy is reviewed, demonstrating, in both historically controlled and randomized studies, the validity of the dose-response concept in MM in terms of increased CR rates as well as extended event-free (EFS) and overall survival (OS). Avoidance of hematopoietic stem cell-damaging agents, especially melphalan, nitrosoureas, and ionizing radiation to marrow-containing sites, assures the ability of peripheral stem cell collection of high quality and quantity, providing rapid engraftment so that mortality is well under 5% following high-dose melphalan (200 mg/m2). This treatment can be applied safely to patients even >70 years of age and in the presence of renal failure. Tandem autotransplants after multiregimen induction have yielded CR rates in the 40% range with median durations of EFS and OS of 43 and 62 months, respectively. Certain chromosomal abnormalities (11 and 13; and translocations) represent the dominant adverse prognosticator for EFS and OS, confirmed in over 500 patients including those with prior therapy. Allogeneic transplants, possible in less than 10% of MM patients, are associated with a 50% mortality during the first year and, unfortunately, late relapses; thus, this approach should be reserved for patients with high-risk disease early in their management. A risk-based treatment algorithm that matches a patient's disease risk with the risk of intervention is presently used, followed by bisphosphonate therapy, not only to delay the onset of MM-related bone disease but also to induce tumor cell apoptosis, indirectly or directly, by down-regulation of cytokines with antiapoptotic activities. Although many patients relapse, this author subscribes to his mentor's motto: "Be Prepared for Success!".  (+info)

Patients following autologous stem cell transplantation are more susceptible to chemotherapy induced bone marrow toxicity. In the present study, bone marrow primitive progenitor cells were examined one year following autologous stem cell transplantation and compared with normal bone marrow and mobilized peripheral blood stem cells. Post-transplantation bone marrow contained a significant lower percentage of quiescent cells in the CD34+/CD38low fraction compared to normal bone marrow. In addition, we observed a strongly decreased stem cell/primitive progenitor frequency in post-transplantation CD34+ cells as defined by long-term culture assays. Measurement of the levels of reactive oxygen species by flow cytometry revealed comparable levels in post-transplantation and normal bone marrow CD34+/CD38low cells, while significantly higher levels of reactive oxygen species were observed in CD34+/CD38high cells following autologous stem cell transplantation compared to normal bone marrow. Moreover, ...
TY - JOUR. T1 - Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation. T2 - Extended follow-up of the multicohort single-arm phase II checkmate 205 trial. AU - Armand, Philippe. AU - Engert, Andreas. AU - Younes, Anas. AU - Fanale, Michelle. AU - Santoro, Armando. AU - Zinzani, Pier Luigi. AU - Timmerman, John M.. AU - Collins, Graham P.. AU - Ramchandren, Radhakrishnan. AU - Cohen, Jonathon B.. AU - De Boer, Jan Paul. AU - Kuruvilla, John. AU - Savage, Kerry J.. AU - Trneny, Marek. AU - Shipp, Margaret A.. AU - Kato, Kazunobu. AU - Sumbul, Anne. AU - Farsaci, Benedetto. AU - Ansell, Stephen M.. PY - 2018/5/10. Y1 - 2018/5/10. N2 - Purpose Genetic alterations causing overexpression of programmed death-1 ligands are near universal in classic Hodgkin lymphoma (cHL). Nivolumab, a programmed death-1 checkpoint inhibitor, demonstrated efficacy in relapsed/refractory cHL after autologous hematopoietic cell transplantation (auto-HCT) ...
TY - JOUR. T1 - Cryptococcal meningitis following autologous stem cell transplantation in a patient with multiple myeloma. AU - Mendpara, S. D.. AU - Ustun, C.. AU - Kallab, A. M.. AU - Mazzella, F. M.. AU - Bilodeau, P. A.. AU - Jillella, A. P.. N1 - Copyright: Copyright 2008 Elsevier B.V., All rights reserved.. PY - 2002/8. Y1 - 2002/8. UR - UR - U2 - 10.1038/sj.bmt.1703646. DO - 10.1038/sj.bmt.1703646. M3 - Letter. C2 - 12203144. AN - SCOPUS:0036676771. VL - 30. SP - 259. EP - 260. JO - Bone Marrow Transplantation. JF - Bone Marrow Transplantation. SN - 0268-3369. IS - 4. ER - ...
RATIONALE: Drugs used in chemotherapy, such as carboplatin, thiotepa, and etoposide, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Isotretinoin may be effective in preventing recurrence of glioma. It is not yet known which regimen of chemotherapy plus autologous stem cell transplantation with or without isotretinoin is more effective in treating recurrent high-grade glioma.. PURPOSE: This randomized phase III trial is studying high-dose chemotherapy or intermediate-dose chemotherapy followed by autologous stem cell transplantation to see how well it works compared to high-dose chemotherapy or intermediate-dose chemotherapy followed by autologous stem cell transplantation and isotretinoin in treating young patients with recurrent high-grade glioma. ...
We conducted a pilot study in 20 patients with high-risk or recurrent/refractory non-Hodgkins lymphoma (NHL) using high-dose sequential chemotherapy (HDSC) and autologous hematopoietic cell transplantation (AHCT). After cytoreduction with standard salvage therapy, HDSC/AHCT was administered in 4 phases at 2- to 4-week intervals. Phase 1 consisted of cyclophosphamide 7 g/m2 followed by granulocyte colony-stimulating factor (G-CSF) at 10 microg/kg per day and leukapheresis upon recovery from white blood cell nadir. The hematopoietic cell product was enriched by Percoll gradient separation and purged with a B-cell or T-cell monoclonal antibody panel and complement. Phase 2 consisted of methotrexate 8 g/m2 with leucovorin rescue and vincristine 1.4 mg/m2. Phase 3 was etoposide 2 g/m2 with G-CSF 5 microg/kg per day. In phase 4, the preparative regimen of mitoxantrone 60 mg/m2 and melphalan 180 mg/m2 was administered followed by AHCT. The NHL histologies were diffuse large cell, follicular/diffuse ...
TY - JOUR. T1 - Autologous blood stem cell versus bone marrow transplantation. AU - Korbling, M.. AU - Juttner, C.. AU - Henon, P.. AU - Kessinger, A.. PY - 1992. Y1 - 1992. UR - UR - M3 - Article. C2 - 1355683. AN - SCOPUS:0026752883. VL - 10. SP - 144. EP - 148. JO - Bone Marrow Transplantation. JF - Bone Marrow Transplantation. SN - 0268-3369. IS - SUPPL. 1. ER - ...
A favourable course of Crohn disease has been observed after allogeneic bone marrow transplantation, and there is now mounting evidence that autologous stem cell may be an effective treatment for severe autoimmune diseases. Here, we present the first long-term endoscopic follow-up of a patient with Crohn disease undergoing autologous stem cell transplantation for haematological disease. A 54-year-old woman developed Crohn disease and was submitted to ileocaecal resection. Four months after surgery, the patient contracted acute myeloid leukaemia. She was initially treated with chemotherapy, and subsequently underwent autologous stem cell transplantation. Following transplantation, the patient has remained in clinical remission regarding both diseases, without anti-inflammatory medication. She has undergone ileo-colonoscopy with normal findings at 1, 2, 3 and 5 years after transplantation. This case suggests that autologous stem cell transplantation can change not only the clinical course, but ...
Evaluate the effectiveness of TXA127 in accelerating the time to initial platelet recovery following PBSC transplant with a limited number of CD34+ cells, defined as CD34+ cell concentrations ≥1.5 x 106 and ≤5.0 x 106 CD34+ cells/kg. Platelet recovery is defined as that day the subject achieves a post-nadir platelet count of ≥20 x 109/L with no platelet transfusion in the prior 7 days ...
High-dose chemotherapy and autologous stem cell transplantation involves the administration of high doses of anti-cancer drugs and/or radiation therapy for the purpose of killing cancer cells, followed by the infusion of stem cells to rescue or restore bone marrow blood cell production. It is important to understand that high-dose chemotherapy is the treatment for your cancer and damage to the bone marrow is a side effect. Fortunately, the bone marrow can be rescued or replaced with stem cells. For autologous stem cell transplantation, stem cells are collected from the patient before high-dose chemotherapy is delivered. The stem cells are collected form the bone marrow or peripheral blood, processed, frozen and stored. Since these cells are collected from the patient, they are referred to as autologous stem cells and the term autologous stem cell transplantation refers to either bone marrow or peripheral blood stem cell transplantation.. High-dose chemotherapy and autologous stem cell ...
Minimal residual disease (MRD) is a powerful determinant of overall outcome in multiple myeloma (MM). Previous studies have demonstrated that the presence of MRD at the traditional day 100 assessment point following autologous stem cell transplant (ASCT) independently predicts for both progression-free (PFS) and overall survival (OS). This effect on outcome is demonstrable in patients achieving a complete response (CR) and in those with both high-risk and standard-risk cytogenetics.1-4 As a consequence, MRD assessment is currently being considered as a surrogate end point for survival in academic clinical trials and for regulatory drug approval.5,6 Surrogate end points are clearly desirable in MM given the increasing complexity of treatment schedules and continually improving complete response rates and survival, such that trials of up-front therapy require 5-10 years of follow up in order to demonstrate survival differences. Acceptance of MRD as an appropriate end point would also ideally ...
As you know, autologous stem cell transplantation remains one of the most effective ways to treat myeloma. Any what we call transplant eligible patient who is fit enough, with not too much comorbidity, should get at some point an autologous stem cell transplantation. That remains true even though we have outstanding new drugs, new proteasome inhibitors, new IMiDs and combinations giving, indeed, excellent results. But still today, and that has been shown with numerous phase III trials comparing an upfront transplant versus a delayed one, every time the upfront transplant, autologous stem cell transplant, was superior and actually the very last trial was performed by the IFM in collaboration with the DFCI, the Americans, this is impress actually and the patients very briefly got VRD, Velcade Revlimid dex, and upfront transplant versus a delayed one at relapse and the option of upfront transplant was largely superior to the delayed one.. Now, even though we are improving myeloma treatment, relapse ...
After autologous hematopoietic cell transplantation (HCT) in the first complete remission (CR1), patients with acute myeloid leukemia (AML) may relapse and undergo allogeneic HCT in the second complete remission (CR2). The aim of this study was to analyze the outcome of allogeneic HCT performed in CR2 comparing patients with prior consolidation by autologous HCT versus patients with chemotherapy consolidation. Included were 2619 adults with allogeneic HCT in CR2 from 2000 to 2017 with (n = 417) or without (n = 2202) prior autologous HCT. Patient groups were not entirely comparable; patients with prior autologous HCT were younger, had less often a favorable cytogenetic profile, had more commonly donors other than matched siblings, and more often received reduced-intensity conditioning. In multivariate analysis, nonrelapse mortality risks in patients with prior autologous HCT were 1.34 (1.07 to 1.67; P =.01) after adjustment for age, cytogenetic risk, transplant year, donor, conditioning ...
Bone marrow transplantation, 1993; 11 (1) doi:. Authors: Hardingham J E, Kotasek D, Sage R E, Dobrovic A, Gooley T Hardingham J E, Kotasek D, Sage R E, Dobrovic A, Gooley T, Dale B M et al.(1) Affiliation: Queen Elizabeth Hospital, Woodville Australia Sample size: 10 Abstract: Twenty-seven patients with non-Hodgkins lymphoma (NHL) have undergone peripheral blood stem cell (PBSC) harvesting for autologous transplantation (Tx). A molecular marker was found at presentation in 23/27 patients. Immunoglobulin heavy chain (IgH) or T cell receptor beta (TCR beta) rearrangements were detected by Southern blotting or the polymerase chain reaction (PCR) in 13 patients; PCR detected the bcl-2/JH fusion in 10 patients. Fifteen autologous PBSC transplants have been performed in 11 patients. In 5/11 patients, the marker was present in at least one PBSC collection (in four patients, every PBSC collection was positive). Survival data are available for nine patients (two early deaths); three patients relapsed ...
Background: First-generation autologous chondrocyte implantation has limitations, and introducing new effective cell sources can improve cartilage repair. Purpose: This study was conducted to compare the clinical outcomes of patients treated with first-generation autologous chondrocyte implantation to patients treated with autologous bone marrow-derived mesenchymal stem cells (BMSCs). Study Design: Cohort study; Level of evidence, 3. Methods: Seventy-two matched (lesion site and age) patients underwent cartilage repair using chondrocytes (n = 36) or BMSCs (n = 36). Clinical outcomes were measured before operation and 3, 6, 9, 12, 18, and 24 months after operation using the International Cartilage Repair Society (ICRS) Cartilage Injury Evaluation Package, which included questions from the Short-Form Health Survey, International Knee Documentation Committee (IKDC) subjective knee evaluation form, Lysholm knee scale, and Tegner activity level scale. Results: There was significant improvement in the ...
TY - JOUR. T1 - Autologous bone marrow mononuclear cells therapy attenuates activated microglial/macrophage response and improves spatial learning after traumatic brain injury.. AU - Bedi, Supinder S.. AU - Walker, Peter A.. AU - Shah, Shinil K.. AU - Jimenez, Fernando. AU - Thomas, Chelsea. AU - Smith, Philippa. AU - Hetz, Robert A.. AU - Xue, Hasen. AU - Pati, Shibani. AU - Dash, Pramod K.. AU - Cox, Charles S.. PY - 2013/1/1. Y1 - 2013/1/1. N2 - Autologous bone marrow-derived mononuclear cells (AMNCs) have shown therapeutic promise for central nervous system insults such as stroke and traumatic brain injury (TBI). We hypothesized that intravenous injection of AMNC provides neuroprotection, which leads to cognitive improvement after TBI. A controlled cortical impact (CCI) rodent TBI model was used to examine blood-brain barrier (BBB) permeability, neuronal and glial apoptosis, as well as cognitive behavior. Two groups of rats underwent CCI with AMNC treatment (CCI-autologous) or without AMNC ...
Sarcoma is a peer-reviewed, Open Access journal dedicated to publishing papers covering all aspects of connective tissue oncology research. It brings together work from scientists and clinicians carrying out a broad range of research in this field, including the basic sciences, molecular biology and pathology and the clinical sciences of epidemiology, surgery, radiotherapy and chemotherapy. High-quality papers concerning the entire range of bone and soft tissue sarcomas in both adults and children, including Kaposis sarcoma, are published as well as preclinical and animal studies.
Objectives: The efficacy and safety of plerixafor, an antagonist of the CXCR4 receptor, in combination with G-CSF has been demonstrated in patients suffering from Iymphoma and multiple myeloma (MM) eligible for autologous haematopoietic stem cell collection. However, different reimbursement criteria have been applied in different countries to select patients eligible for treatment with plerixafor. The objective of this observational study was to describe the plerixafor prescription modalities in daily practice in Belgium. Methods: This open-label, prospective, observational study was conducted in 11 Belgian centres in 114 patients with lymphoma (Hodgkins and non-Hodgkins lymphoma) or MM who were treated with plerixafor according to the SmPC between April 2011 and October 2012. Patients included in another clinical trial with plerixafor were excluded from the study. Results: The use of plerixafor in patients with MM or lymphoma was effective, with a success rate (defined as a total yield > 2 x ...
Autologous stem cell transplant harvests your own stem cells from your body, stores them and injects them back into your body following another potentially harmful treatment like, chemotherapy or radiation. The stem cells are collected through a process called Bone Marrow Aspiration. International Healthcare Providers can guide you through the minefield of researching and selecting a healthcare solution tailored to your needs. We will work with you at every stage to help you better understand the current state of the research and offer you peace of mind, comfort, and security.. You have choices and control when it comes to taking care of your health. International Healthcare Providers can bring you premium access to the best healthcare in North America and help you find a specialist who will walk you through an autologous stem cell transplant.. Autologous stem cell transplants are used in the treatment of a variety of cancers as well as treating musculoskeletal issues. If you think this ...
Autologous stem cell transplantation for the treatment of neuroblastoma in Korea.: Autologous stem cell transplantation (ASCT) for the treatment of high-risk ne
Background. The role of single vs double autologous stem cell transplantation (ASCT) for newly diagnosed (ND) multiple myeloma (MM) continues to be debated in the novel agent era. Methods. The phase III EMN02/HO95 study was designed to administer 3-4 cycles of bortezomib-cyclophosphamide-dexamethasone as induction therapy for NDMM and afterwards to randomize eligible patients to receive (randomization 1, R1) standard-dose intensification treatment with bortezomib-melphalan-prednisone (VMP) for four 42-day cycles or high-dose intensification treatment with melphalan at 200 mg/m2 (HDM) plus ASCT. A second randomization to receive or not receive consolidation therapy was planned after the intensification phase, followed by lenalidomide maintenance in both arms. In centers committed to a double ASCT policy, patients were randomized (1:1:1) to receive VMP or single ASCT (ASCT-1) or two sequential courses of HDM (administered 2 to 3 months apart) plus double ASCT (ASCT-2) in order to prospectively ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
The prognosis of brain tumors in children has improved for the last 2-3 decades. However, the prognosis remains dismal in patients with relapsed tumors. The outcome for infants and young children is also poor. For younger children, the ability to use of radiotherapy (RT) is very limited because of the unacceptable long-term adverse effects of RT. The prognosis is also not satisfactory when a large residual tumor remains after surgery or when leptomeningeal seeding is present at diagnosis. In this context, a strategy using high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT) has been explored to improve the prognosis of recurrent or high-risk brain tumors. It was found that at least some patients with relapsed tumors can be salvaged with HDCT/autoSCT. For infants and young children, it was possible to avoid or defer RT until 3 years of age while maintaining or improving survival rates. Investigators also have explored the efficacy of HDCT/autoSCT in patients with newly ...
TY - JOUR. T1 - Progenitor and lymphoma cells in blood stem cell harvests. T2 - Impact on survival following transplantation. AU - Demirkazik, A.. AU - Kessinger, A.. AU - Armitage, J. O.. AU - Bierman, P. J.. AU - Lynch, J.. AU - Vose, J.. AU - Chan, W.. AU - Sharp, J. G.. PY - 2001. Y1 - 2001. N2 - This study evaluated whether cytokine-induced blood stem cell mobilization also mobilized lymphoma cells and whether lymphoma cell mobilization affected outcome post autologous blood stem cell transplant. Blood stem cell collections from 26 non-Hodgkins lymphoma (NHL) patients harvested during steady-state (non-mobilized) and from 35 NHL patients harvested after cytokine administration (mobilized) were studied. The harvests were cultured and molecularly evaluated for clonal markers of the primary lymphoma. All patients underwent high-dose chemotherapy and autologous transplantation. Graft products from mobilized patients were more likely to contain lymphoma than graft products from non-mobilized ...
TY - JOUR. T1 - Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function. T2 - The LateTIME randomized trial. AU - Traverse, Jay H.. AU - Henry, Timothy D.. AU - Ellis, Stephen G.. AU - Pepine, Carl J.. AU - Willerson, James T.. AU - Zhao, David X.M.. AU - Forder, John R.. AU - Byrne, Barry J.. AU - Hatzopoulos, Antonis K.. AU - Penn, Marc S.. AU - Perin, Emerson C.. AU - Baran, Kenneth W.. AU - Chambers, Jeffrey. AU - Lambert, Charles. AU - Raveendran, Ganesh. AU - Simon, Daniel I.. AU - Vaughan, Douglas E.. AU - Simpson, Lara M.. AU - Gee, Adrian P.. AU - Taylor, Doris A.. AU - Cogle, Christopher R.. AU - Thomas, James D.. AU - Silva, Guilherme V.. AU - Jorgenson, Beth C.. AU - Olson, Rachel E.. AU - Bowman, Sherry. AU - Francescon, Judy. AU - Geither, Carrie. AU - Handberg, Eileen. AU - Smith, Deirdre X.. AU - Baraniuk, Sarah. AU - Piller, Linda B.. AU - Loghin, Catalin. AU - Aguilar, ...
TY - JOUR. T1 - Therapeutic effects of concurrent autologous bone marrow cell infusion and metabolic intervention in ischemia-induced angiogenesis in the hypercholesterolemic mouse hindlimb. AU - de Nigris, Filomena. AU - Williams-Ignarro, Sharon. AU - Sica, Vincenzo. AU - DArmiento, Francesco P.. AU - Lerman, Lilach O.. AU - Byrns, Russell E.. AU - Sica, Giacomo. AU - Fiorito, Carmela. AU - Ignarro, Louis J.. AU - Napoli, Claudio. PY - 2007/4/25. Y1 - 2007/4/25. N2 - Lower-limb ischemia is a major health problem especially when associated to hypercholesterolemia. Because of the absence of effective treatment in the advanced stages of the disease, amputation is undertaken to alleviate unbearable symptoms. Since tissue ischemia and hypercholesterolemia are associated with an overwhelming generation of oxygen radicals, metabolic intervention with antioxidants and l-arginine can induce beneficial effects beyond those achieved by a novel therapeutic approach represented by the use of autologous ...
TY - JOUR. T1 - Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. AU - Rahman, Zia. AU - Kavanagh, John. AU - Champlin, Richard. AU - Giles, Richard. AU - Hanania, Elie. AU - Fu, Siqinq. AU - Zu, Zifei. AU - Mehra, Rakesh. AU - Holmes, Frankie. AU - Kudelka, Andrzej. AU - Claxton, David. AU - Verschraegen, Claire. AU - Gajewski, James. AU - Andreeff, Michael. AU - Heimfeld, Shelly. AU - Berenson, Ronald. AU - Ellerson, Debra. AU - Calvert, Leslie. AU - Mechetner, Eugene. AU - Holzmayer, Tanya. AU - Dayne, Andrew. AU - Hamer, Joy. AU - Bachier, Carlos. AU - Ostrove, Jeffrey. AU - Przepiorka, Donna. AU - Burtness, Barbara. AU - Cote, Richard. AU - Bast, Robert. AU - Hortobagyi, Gabriel. AU - Deisseroth, Albert. PY - 1998/11/1. Y1 - 1998/11/1. N2 - Most patients relapse after high-dose chemotherapy (HDCT) with autologous stem-cell transplantation (ASCT) for metastatic breast cancer. Further chemotherapy immediately after hematopoietic ...
TY - JOUR. T1 - Patients mobilizing large numbers of CD34+ cells (super mobilizers) have improved survival in autologous stem cell transplantation for lymphoid malignancies. AU - Bolwell, B. J.. AU - Pohlman, B.. AU - Rybicki, L.. AU - Sobecks, R.. AU - Dean, R.. AU - Curtis, J.. AU - Andresen, S.. AU - Koo, A.. AU - Mineff, V.. AU - Kalaycio, M.. AU - Sweetenham, J. W.. PY - 2007/9/1. Y1 - 2007/9/1. N2 - The cellular composition of an autologous graft may influence autologous stem cell transplantation (ASCT) outcome. Etoposide (VP) plus filgrastim (G) frequently mobilizes high numbers of CD34+ cells for autologous transplantation. We investigated whether patients collecting high numbers of CD34+ cells (super mobilizers) have a better outcome than other patients. We reviewed 350 consecutive adult patients with NHL or Hodgkins lymphoma receiving an ASCT from January 1994 to December 2005, mobilized with VP+G. Super mobilizers were defined as collecting a minimum of 8 × 106 CD3+ cells/kg. ...
Anna J. Kopinska, Grzegorz Helbig, Anna Koclega, Slawomira Kyrcz Krzemien. Bing-Neel Syndrome with Detectable MYD88 L265P Gene Mutation as a Late Relapse Following Autologous Hematopoietic Stem Cell Transplantation for Waldenstr m s Macroglobulinemia. Turk J Hematol. 2017; 34(2): 186- ...
BACKGROUND: Follicular lymphoma (FL) is the most common indolent and second most common Non-Hodgkin`s lymphoma (NHL) in the Western world. Standard treatment usually includes rituximab and chemotherapy. High-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) is an option for patients in advanced stages or for second-line therapy, leading to improved progression-free survival (PFS) rates. However, the impact of HDT and ASCT remains unclear, as there are hints of an increased risk of second cancers.. OBJECTIVES: We performed a systematic review with meta-analysis of randomised controlled trials (RCTs) comparing HDT plus ASCT with chemotherapy or immuno-chemotherapy in patients with FL with respect to overall survival (OS), PFS, treatment-related mortality (TRM), adverse events and secondary malignancies.. SEARCH METHODS: We searched CENTRAL, MEDLINE, and EMBASE as well as conference proceedings from January 1985 to September 2011 for RCTs. Two review authors independently ...
Autologous stem cell transplants are done using peripheral blood stem cell transplantation (PBSCT). With PBSCT, the stem cells are taken from blood. The growth factor G-CSF may be used to stimulate the growth of new stem cells so they spill over into the blood. G-CSF is a protein that is produced naturally in the body. The blood is removed from a vein and passed through a machine that separates the stem cells. The machine then returns the remaining blood through a needle in the persons arm or through a central venous catheter. This way of collecting stem cells is called apheresis.. In adults, most autologous transplants use stem cells from blood. In a child, the decision whether to use cells from the bone marrow or the blood depends on the size of the child.. ...
Instantly find & access educational materials and complete eLearning activities at your leisure. Native iPad/iPhone/Android Apps are available for the convenience of on-the-go users.
Hematopoietic precursor cells (HPC) are able to restore hematopoiesis after high-dose chemotherapy and their cryopreservation is routinely employed prior to the autologous hematopoietic cell transplantation (AHCT). Although previous studies showed feasibility of long-term HPC storage, concerns remai
Renal impairment (RI) is a negative prognostic factor in Multiple Myeloma (MM) and affected patients are often excluded from autologous stem cell transplantation (ASCT). However, it remains unclear whether historically inferior outcome data still hold true. From a total of 475 eligible MM patients who had undergone ASCT between 1998 and 2016, 374 were included in this multi-centric retrospective cohort study. Renal function was determined both at the time of MM diagnosis and ASCT by estimated glomerular filtration rate (eGFR according to the MDRD formula, RI defined as eGFR | 60 ml/min/1.73m2). Patients were categorized into 3 groups: A) no RI diagnosis and ASCT, B) RI at diagnosis with normalization before ASCT and C) RI both at the time of diagnosis and ASCT. Log-rank testing was used for overall and progression-free survival (OS, PFS) analysis. While severe RI at MM diagnosis confers a risk of shorter OS, MM progression after ASCT is not affected by any stage of renal failure. It can be concluded
The Transplant Committee of the Cancer and Leukemia Group B (CALGB) was organized in the mid-1980s at a time when high-dose chemotherapy with autologous bone marrow transplant was being actively investigated as treatment for a number of solid tumors and hematologic malignancies. Preliminary data from single institution studies had generated considerable interest in the use of high-dose chemotherapy and autologous bone marrow transplant for both metastatic and early-stage high-risk breast cancer, so that such treatment was widely employed at many centers despite the lack of definitive evidence from controlled trials that it was efficacious. Therefore, CALGB designed protocol 9082 to definitively test whether high-dose chemotherapy and autologous bone marrow transplant was superior to intermediate dose chemotherapy in women with stage II breast cancer and ≥10 positive axillary lymph nodes (1).. At the time this trial was initiated, the role of autologous transplantation as treatment for ...
Autologous stem cell transplantation (ASCT) has been employed for patients with relapsed multiple myeloma (MM) after up-front ASCT. The present retrospective study aimed to examine the survival benefit from salvage ASCT. Among 446 patients with relapsed MM after up-front single ASCT, 70 patients rec
Maintenance Therapy with Immunomodulatory Drugs after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Autologous transplantation of endothelial progenitor cells (EPCs) is a promising therapeutic approach in the treatment of various vascular diseases. We previously reported a two-step culture system for scalable generation of human EPCs derived from cord blood CD34+ cells ex vivo. Here, we now apply this culture system to expand and differentiate human and nonhuman primate EPCs from mobilized peripheral blood (PB) CD34+ cells for the therapeutic potential of autologous transplantation. The human and nonhuman primate EPCs from mobilized PB CD34+ cells were cultured according to our previously reported system. The generated adherent cells were then characterized by the morphology, surface markers, nitric oxide (NO)/endothelial NO synthase (eNOS) levels and Dil-acetylated low-density lipoprotein (Dil-Ac-LDL) uptake/fluorescein isothiocyanate (FITC)-lectin binding actives. Furthermore, the efficacy and safety studies were performed by autologous transplantation via hepatic portal vein injection in a nonhuman
definition of ABMR, what does ABMR mean?, meaning of ABMR, Autologous Bone Marrow Reinfusion, ABMR stands for Autologous Bone Marrow Reinfusion
Josh D. Epworth, MSN, ARNP, of the University of Washington Medical Center, discusses study findings on maintenance therapy with the oral proteasome inhibitor ixazomib, which significantly prolonged progression-free survival following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma (Abstract 301).. ...
TY - JOUR. T1 - Tandem high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation for recurrent soft tissue sarcoma. AU - Kozuka, Teruhiko. AU - Kiura, Katsuyuki. AU - Katayama, Hideki. AU - Fujii, Nobuharu. AU - Ishimaru, Fumihiko. AU - Ikeda, Kazuma. AU - Ueoka, Hiroshi. AU - Hamasaki, Shuuji. AU - Yoshino, Tadashi. AU - Kashihara, Yoshio. AU - Date, Hiroshi. AU - Tanimoto, Mitsune. AU - Harada, Mine. PY - 2002/9. Y1 - 2002/9. N2 - Background: Patients with recurrent soft tissue sarcoma (STS) are seldom curable, with 5-year survival rates of less than 10% in all large series. The role of high-dose chemotherapy (HDC) with hematopoietic stem cell support in this disease has not been established. Case Report: We report on two patients with recurrent STS who were treated with tandem HDC supported by autologous peripheral blood stem cell transplantation (PBSCT). One patient with malignant fibrous histiocytoma recurred with multiple lung metastases. This patient ...
Searching for the cost of Autologous Bone Marrow Transplant in Faridabad? Contact Lyfboat to Get an Expert Second Opinion & Personalised Quote for Autologous Bone Marrow Transplant from the best Autologous Bone Marrow Transplant hospitals in Faridabad. We enable patients to connect, communicate and find quality healthcare for Autologous Bone Marrow Transplant in Faridabad.
TY - JOUR. T1 - Rapid immune reconstitution following autologous hematopoietic stem cell transplantation in children. T2 - A single institution experience. AU - Hoepfner, S.. AU - Haut, Paul. AU - OGorman, M.. AU - Kletzel, M.. PY - 2003/2. Y1 - 2003/2. N2 - In this retrospective study, we review the immune reconstitution of children undergoing autologous hematopoietic stem cell transplantation. A total of 125 patients underwent autologous transplantation between 1992 and 2000. The report includes data on 58 patients. Data were not available on the remaining patients who either died before testing or data were not obtained. The parameters evaluated include: (a) immunophenotype by flow cytometry to quantify lymphocyte subpopulations (b) mitogen stimulation assays, and (c) quantitative immunoglobulins. The analysis reveals that CD3+ cells did not reach the normal range during the first year post-transplant. The median percentage of CD4 + cells was below normal up to 6 months post-transplant, ...
TY - JOUR. T1 - A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory Non-Hodgkin lymphoma. AU - Srivastava, Shivani. AU - Jones, David. AU - Wood, Lisa L.. AU - Schwartz, Jennifer E.. AU - Nelson, Robert P.. AU - Abonour, Rafat. AU - Secrest, Angie. AU - Cox, Elizabeth. AU - Baute, Jay. AU - Sullivan, Cheryl. AU - Kane, Kathleen. AU - Robertson, Michael J.. AU - Farag, Sherif S.. PY - 2011/7/1. Y1 - 2011/7/1. N2 - Clofarabine has significant single-agent activity in patients with indolent and aggressive non-Hodgkin lymphoma and synergizes with DNA-damaging drugs. Treatment, however, may be associated with severe and prolonged myelosuppression. We conducted a phase I trial to determine the maximum tolerated dose (MTD) of clofarabine in combination with high-dose etoposide and cyclophosphamide followed by autologous peripheral blood stem cell ...
Objectives: To carry out a phase I-II trial to elucidate the feasibility and efficacy of high dose cyclophosphamide (CY) supported by autologous peripheral blood stem cell transplantation (PBSCT) in the treatment of severe and refractory autoimmune disease (AD).. Methods: Peripheral blood stem cells (PBSCs) were mobilised during haematological recovery after relatively high dose CY (2 g/m2) for 2 days, followed by administration of granulocyte colony stimulating factor. After collecting PBSCs-more than 2×106 CD34+ cells/kg-by apheresis, CD34+ cells were immunologically selected and cryopreserved. Eight patients were enrolled-five had systemic sclerosis (SSc) alone, one had SSc with systemic lupus erythematosus, one amyopathic dermatomyositis (ADM), and one Wegeners granulomatosis (WG). All of the patients were treated with high dose CY (50 mg/kg) for 4 days and autologous PBSCT.. Results: Haematopoietic reconstitution was rapid and sustained. Toxicity due to the regimen included various ...
The role of autologous peripheral blood stem cell transplantation (APBSCT) in acute myeloid leukaemia (AML) remains controversial. The current study evaluated the application of APBSCT in a large consecutive series of patients with untreated AML, and compared outcome with a predictive model based on MRC AML10 data. Of 148 evaluable patients, 118 patients entered complete remission (CR) after induction therapy comprising three cycles of daunorubicin, cytosine arabinoside and oral 6-thioguanine. Of these patients, 68 (57%) proceeded to consolidation therapy with two courses of intermediate dose cytosine arabinoside, and stem cell mobilisation, and 40 of these patients (34%) underwent the APBSCT procedure after high dose busulphan conditioning. Harvest quality was the main factor precluding APBSCT. Five-year event-free survival (EFS) in patients who achieved CR was 38% and in APBSCT patients was 57%. There were no transplant-related deaths. No significant differences were demonstrated between ...
BACKGROUND: Allogeneic stem cell transplantation is usually considered the only curative treatment option for patients with advanced or transformed myelodysplastic syndromes in complete remission, but post-remission chemotherapy and autologous stem cell transplantation are potential alternatives, especially in patients over 45 years old. DESIGN AND METHODS: We evaluated, after intensive anti-leukemic remission-induction chemotherapy, the impact of the availability of an HLA-identical sibling donor on an intention-to treat basis. Additionally, all patients without a sibling donor in complete remission after the first consolidation course were randomized to either autologous peripheral blood stem cell transplantation or a second consolidation course consisting of high-dose cytarabine. RESULTS:
TY - JOUR. T1 - Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. AU - Sauter, Craig S.. AU - Matasar, Matthew J.. AU - Meikle, Jessica. AU - Schoder, Heiko. AU - Ulaner, Gary A.. AU - Migliacci, Jocelyn C.. AU - Hilden, Patrick. AU - Devlin, Sean M.. AU - Zelenetz, Andrew D.. AU - Moskowitz, Craig. PY - 2015/4/16. Y1 - 2015/4/16. N2 - High-dose chemotherapy (HDT) plus autologous stem cell transplantation (ASCT) is the standard of care for chemosensitive relapsed and refractory diffuse large B-cell lymphoma (rel/ref DLBCL). Interim restaging with functional imaging by positron emission tomography using 18F-deoxyglucose (FDG-PET) has not been established after salvage chemotherapy (ST) and before HDT-ASCT by modern criteria. Herein, we evaluated 129 patients with rel/ref DLBCL proceeding to HDT-ASCT, with ST response assessment by FDG-PET according to the contemporary Deauville 5-point scale. At 3 years, patients ...
HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients compromised immune systems would have a higher risk of infection and poor graft function due to their need for HIV medications. Results from the clinical trial, presented at the American Society of Hematology (ASH) meetings on December 8 at 4:45 p.m. PST, show the concern of additional risk is unfounded. Patients with HIV-associated lymphoma (HAL) who meet standard eligibility criteria should receive an autologous blood stem cell transplant as standard of care or be enrolled in a National Institutes of Health (NIH)-funded clinical trial.. The single-arm, multi-institutional clinical trial-conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) in collaboration with the AIDS Malignancy Clinical Trials Consortium (AMC)-followed the progress of 40 patients with treatable HIV-1 infection 15 years of age and ...
The search strategy had the broad aim of the retrieval of all relevant studies. With respect to historical versions of the Cochrane Review,10 we applied two different search strategies and retrieved the same studies with aggregate data but different studies with individual cases data. These results show the substantial difficulty associated with the aim of searching for all published cases. This enterprise appears almost impossible. We adopted the new WHO 2013 classification of STS and made minor modifications to define a clear terminology for the study selection process. The group of NRSTS consists of many subtypes that are difficult to diagnose and separate even today. A considerable number of tumours cannot be clearly assigned to a specific histological category. Thus, we may have tumours with a specific label that might not be true. Otherwise, we may have tumours without a specific label that might belong to a specific category. We excluded studies if the proportion of non-eligible ...
Autologous Hematopoietic Stem Cell Transplantation in 48 Patients With End-Stage Chronic Liver Diseases The only presently viable treatment for end-st... &issue=Suppl. 1&spage=S154&epage=&date=1997&atitle=Autologous+peripheral+blood+stem+cell+(PBSC)+transplantation+after+megatherapy+for+paediatric+patients+with+high+risk+malignancy:+a+feasible+ ...
Looking for online definition of autotransplants in the Medical Dictionary? autotransplants explanation free. What is autotransplants? Meaning of autotransplants medical term. What does autotransplants mean?
New data supports the safety and efficacy of GSKs Shingrix in preventing shingles in autologous haematopoietic stem cell transplant patients
Results The median Inflammatory Neuropathy Cause and Treatment (INCAT) score within 1 month prior to AHSCT was 6 and the Rankin score 4. Total INCAT and Rankin scores improved significantly within 2-6 months after AHSCT and continued to do so at last follow-up. The motor action potential amplitudes (CMAP) improved already within 4 months (median) after AHSCT. Three of the 11 patients relapsed during the follow-up period, requiring retransplantation with AHSCT in one. Eight of the 11 patients maintained drug-free remission upon last follow-up. AHSCT was safe but on the short term associated with a risk of cytomegalovirus (CMV) and Epstein-Barr virus reactivation, CMV disease, haemorrhagic cystitis and pancreatitis.. ...
Intensive chemoradiotherapy, with or without additional local radiotherapy, and unpurged autologous marrow transplantation was given to 68 patients with progressive non-Hodgkins lymphoma. Responses were attained in 44 patients (65%, 95% confidence intervals [CI], 52% to 76%), including 37 who achieved complete responses. Fifteen patients (22%, 95% C.I. 13% to 34%) remain free of disease (including 11 continuously) at a median of 5.3 (range 3.1 to 9.1) years later. Higher Karnofsky scores (P less than .01, Mann-Whitney U test) and the absence of a history of prior radiotherapy (P = .02, chi 2 test) were associated with achievement of complete plus partial responses. Higher Karnofsky scores (P less than .01, Mann-Whitney U test) and less resistant disease status at transplantation (P = .04, chi 2 test) were significant when calculations were limited to complete responses. Karnofsky scores were also associated with the probability of freedom from progression (P = .02, log-rank) for responding ...
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you dont have an account you can just enter your email address in the email box below ...
TY - JOUR. T1 - A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors. AU - Adkins, Douglas R.. AU - Irvin, Rebecca. AU - Kuhn, John. AU - Boldt, David H.. AU - Roodman, G. David. AU - Salzman, Donna. AU - Freytes, Cesar. AU - Von Hoff, D. D.. AU - LeMaistre, C. F.. PY - 1993/6. Y1 - 1993/6. N2 - Dacarbazine (DTIC) is a chemotherapy drug which has antitumor activity at standard doses, exhibits a steep dose-response effect in vitro, and is associated with relatively few non-hematologic toxicities. These characteristics suggest a potential role for this drug in bone marrow transplant preparative regimens. To pursue this hypothesis, 16 patients with refractory solid tumors were enrolled in a phase I study of single agent DTIC to determine the dose of DTIC requiring bone marrow reinfusion and to define the dose-limiting toxicity and maximum tolerated dose when given with autologous bone marrow rescue. Pharmacokinetics ...
TY - JOUR. T1 - Autologous bone marrow transplantation for patients with advanced chronic myelogenous leukemia. AU - Nagamura-Inoue, Tokiko. AU - Tojo, Arinobu. AU - Ikebuchi, Kenji. AU - Takahashi, Satoshi. AU - Ogura, Hiromi. AU - Shindoh, Eiichi. AU - Nagamura, Fumitaka. AU - Uemura, Naoki. AU - Watari, Kiyoshi. AU - Irie, Seiji. AU - Setoyama, Misao. AU - Tajika, Kenji. AU - Nakayama, Michihiro. AU - Nagayama, Hitomi. AU - Kobayashi, Yukio. AU - Shirafuji, Naoki. AU - Sato, Noriharu. AU - Okamoto, Shin ichiro. AU - Ozawa, Keiya. AU - Tani, Kenzaburo. AU - Asano, Shigetaka. PY - 1997/12. Y1 - 1997/12. N2 - We report on seven chronic myelogenous leukemia (CML) patients who received autologous bone marrow transplantation (ABMT) using bone marrow (BM) cells while at the chronic phase (CP) under the various treatments. Of the seven patients, four progressed to accelerated phase (AP) in 83-248 weeks after onset and three patients entered blastic crisis (BC) in 84-171 weeks after onset. All ...
In patients with Hodgkin lymphoma who are at risk for disease progression following autologous stem cell transplantation, early consolidation with brentuximab vedotin (Adcetris) post-transplant significantly improved progression-free survival compared with placebo in the phase III AETHERA trial.1 The median progression-free survival was 43 months for the brentuximab-treated group vs 24 months for the placebo group, representing a significant 43% reduction in the risk of disease progression (P = .001).. In my opinion, once this study is published, brentuximab should be the standard of care for patients with the characteristics in this trial: that is, remission duration less than 1 year, extranodal disease, B symptoms, two or more prior salvage therapies, and primary refractory disease, said lead author Craig Moskowitz, MD, Clinical Director of the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center, New York.. Dr. Moskowitz explained that autologous stem cell ...
To the best of our knowledge, this is the first report of the use of biosimilar G-CSF for the mobilization of PBSC in children committed to autologous transplantation. Biosimilar G-CSF is a cheaper alternative to originator molecule filgrastim. The patent for filgrastim expired in Europe in 2006 and in the United States in 2013. European Medicines Agency has approved several biosimilar versions, three of which are commercially available.[9] Yet, concerns have been raised in 2011 among hematologists on the use of biosimilar G-CSF in stem cell transplant, until sufficient efficacy and safety data are available.[10] The first report of the use of a biosimilar G-CSF for stem cell mobilization for autologous transplantation was published by Lefrère and colleagues in 2011,[11] in whom 40 patients achieved similar mobilization yield and safety profile to the originator G-CSF. Moreover, the biosimilar G-CSF-mobilized cells were able to rescue the patient following high-dose chemotherapy. Speed of both ...
Background:. NY-ESO-1 and LAGE-1a are cancer-testis antigens that are overexpressed in patients with multiple myeloma (MM), and the incidence of these antigens correlates with tumor proliferation and other high-risk features. Genetically engineered NY-ESO-1 SPEAR (specific peptide enhanced affinity receptor) T-cells (NY-ESO-1c259T cells) recognize the peptide sequence SLLMWITQC expressed by NY-ESO-1 or LAGE-1a in the context of HLA-A*02 presentation. This study evaluated treatment with NY-ESO-1 SPEAR T-cells post-autologous stem cell transplant (ASCT) in patients with advanced MM. Methods:. Eligible patients were HLA-A*02:01, 02:05 or 02:06 positive, with refractory, relapsed or high risk MM associated with one or more adverse cytogenetic abnormalities. Eligible patients tumors also expressed NY-ESO-1 and/or LAGE-1a by qPCR. The primary study endpoint was safety. Secondary objectives included overall response rate (ORR) (sCR+CR+VGPR+PR) evaluated with the International Myeloma Working Group ...
Autologous bone marrow or stem cell transplantation has had an important role in the treatment of aggressive lymphoma for several decades. The important results of the PARMA study1 demonstrated that patients in first relapse who remained chemosensitive had improved progression-free and overall survival compared to patients who continued to receive standard-dose salvage therapy. Based on that trial, salvage autologous bone marrow transplantation became the standard of care for these patients and resulted in a long-term progression-free survival rate of approximately 50%.. Consolidation Strategy. If salvage bone marrow transplantation is effective, would consolidation bone marrow transplantation immediately after initial chemotherapy further improve the survival of advanced-stage, aggressive lymphomas? Over the past 2 decades, numerous randomized studies demonstrated no improvement in overall survival when all patients received consolidative autologous bone marrow transplantation or stem cell ...
Ulcerative colitis (UC) is a chronic inflammatory bowel disease with continuous or recurrent symptoms. A 42-year-old male patient with intermittent diarrhe
Brillant C, Skoetz N, Kluge S, Schwarzer G, Trelle S, Greb A, Schulz H, Engert A, Bohlius J. High-dose chemotherapy with autologous stem cell support for first-line treatment of aggressive non-Hodgkin lymphoma: a systematic review and meta-analysis based on individual patient data. Cochrane Database of Systematic Reviews 2016, Issue 12. Art. No.: CD007580. DOI: 10.1002/14651858.CD007580. ...
The results in 34 adult patients with acute myeloid leukemia (AML) who have undergone autologous bone marrow transplantation (ABMT) using busulfan and cyclophosphamide (Bu/Cy) in 12 United Kingdom (UK) centers have been analyzed. There were 19 females and 15 males; median age was 40 years (range, 21 to 62 years). Nine patients were in first relapse; 25 were in second remission. The median time of first remission for the whole group was 11.5 months (range, 1 to 56 months). All the patients in first relapse and six patients in second remission received first remission marrow. The leukemia-free survival (LFS) for the patients in first relapse was 33%, with a median follow-up of 20 months. The LFS for the patients in second remission was 48% with a median follow-up of 26 months. The length of second remission exceeds the length of first remission in 14 patients. Considerable toxicity with hemorrhagic cystitis (four patients; none fatal), venoocclusive disease (four patients; one fatal), pneumonitis ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...
In this MEDtalk Øivind Fredvik Torkildsen present new data who support, that stem cell transplantation is an effective and relatively safe treatment of MS. ...
Background: The combination of Rituximab and CHOP (R-CHOP) is considered to be the standard treatment for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Treatment results are still unsatisfactory in a significant proportion of patients, particularly in those with a high-risk disease defined by the IPI score. The use of high-dose chemotherapy with autologous stem-cell transplantation (ASCT) is standard clinical practice for patients with relapsed/refractory DLBCL, while its significance as consolidation in first-line treatment remains unclear. Aims: We analyzed safety and effectiveness of R-CHOP followed by salvage chemotherapy and ASCT for patients with young (,65 years) high-risk DLBCL, defined by an age-adjusted IPI score of 2/3, for whom from 2004 on our institutional guidelines recommended ASCT as consolidation. We analyzed prognostic factors in this group. Methods: The treatment program consisted of 4 cycles R-CHOP-14 followed by 3 cycles of a DHAP-like salvage ...
In this retrospective multicentre study, we investigated the outcomes of elderly primary central nervous system lymphoma (PCNSL) patients (greater than or equal to65 years) who underwent high-dose chemotherapy followed by autologous stem cell transplantation (HDT-ASCT) at 11 centres between 2003 and 2016. End points included remission, progression-free survival (PFS), overall survival (OS) and treatment-related mortality. We identified 52 patients (median age 68.5 years, median Karnofsky Performance Status before HDT-ASCT 80%) who all underwent thiotepa-based HDT-ASCT. Fifteen patients (28.8%) received HDT-ASCT as first-line treatment and 37 (71.2%) received it as second or subsequent line. Remission status before HDT-ASCT was: CR 34.6%, PR 51.9%, stable disease 3.8% and progressive disease 9.6%. Following completion of HDT-ASCT, 36 patients (69.2%) achieved CR (21.2% first-line setting and 48.1% second or subsequent line setting) and 9 (17.3%) PR (5.8% first-line setting and 11.5% second or subsequent
Clinical trial for Multiple Myeloma , Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen
Limb salvage was possible in all six diabetic patients with Fontaine stage IV CLI following autologous BM MNC injection. The procedure was safe without any adverse outcomes.
The purpose of this study is to evaluate the efficacy and toxicity of tandem HDCT/ASCT including high-dose 131I-metaiodobenzylguanidine (MIBG) treatment. In
Learn more about Other Treatments for Hodgkins Lymphoma: Bone Marrow and Peripheral Stem Cell Transplantation at Doctors Hospital of Augusta Main Page ...
Results Since 2003, 17 pts s-dcSSC were enrolled (4 M, 13 F; median age 40 yrs., ranging 20-62 yrs.), The median follow-up was of 41 months (range 6-136). A beneficial effect was observed in 16/17 pts (94%).The mean mRSS was 20.9 (SD ± 4.0) at baseline (T0), 9.8 (± 4.6) at month 6 (T6), 6.8 (± 2) at month 12 (T12), and 3.0 (± 1.6) at month 60 (T60), (all p,0.001 with respect to T0). The mean ESSG score was 5.2±0.7 at T0, 2.1±0.8 at T6, 2.1±1.8 at T12, and 1.8±0.74 at T60 (all p,0.0001 with respect to T0). OI was nearly unchanged during follow-up. Mean DLCO predicted value was 65.7%±16.8% at T0, 63.2%±12.5% at T12, and 59.8%±16.3% at T60. Mean VC predicted value was 78.7%±22.0% at T0, 83.4%±17.0% at T12, 90.3% ± 26.0% at T60. No echocardiographic changes were identified during follow-up. Two patients died from SSc-related lung and cardiac disease progression, and one patient because of interstitial pneumonia within 100 days after AHSCT, this leading to a TRM of 5.8%.. ...
Heng, B.C.,Phan, T.T.,Liu, H.,Ouyang, H.W.,Cao, T. (2006). Can the therapeutic advantages of allogenic umbilical cord blood-derived stem cells and autologous bone marrow-derived mesenchymal stem cells be combined and synergized?. ASAIO Journal 52 (6) : 611-613. [email protected] Repository. ...
TY - JOUR. T1 - Is there a place for autologous bone marrow transplantation in chronic myeloid leukemia?. AU - Frassoni, F.. AU - Carella, A. M.. PY - 1993. Y1 - 1993. UR - UR - M3 - Article. C2 - 8298470. AN - SCOPUS:0027525235. VL - 11. SP - 1. EP - 3. JO - Stem Cells. JF - Stem Cells. SN - 1066-5099. IS - SUPPL. 3. ER - ...
Melphalan at a dose of 200mg/m2 is standard conditioning prior to autologous haematopoietic stem cell transplantation for multiple myeloma, but a dose of 140mg/m2 is often used in clinical practice in patients perceived to be at risk of excess toxicity. To determine if melphalan 200 and melphalan 140 are equally effective and tolerable in clinically relevant patient subgroups we analysed 1964 first single autologous transplantation episodes using a series of Cox proportional-hazards models. Overall survival, progression-free survival, cumulative incidence of relapse, non-relapse mortality, haematopoietic recovery and second primary malignancy rates were not significantly different between the melphalan 140 (n=245) and melphalan 200 (n=1719) groups ...
9. Bokemeyer C, Franzke A, Hartman JT, et al: A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin 25. Dupuis-Girod S, Hartman O, Benhamou E, et al: Will high dose with peripheral blood stem cell support for the treatment of patients chemotherapy followed by autologous bone marrow transplantation with advanced soft tissue sarcomas. Cancer 80:1221-1227, 1997 supplant cranio-spinal irradiation in young children treated for medul- 10. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, 26. Mason WP, Grovas A, Halpern S, et al: Intensive chemotherapy autologous bone marrow transplantation, and 13-cis-retinoic acid: and bone marrow rescue for young children with newly diagnosed Childrens Cancer Group. N Engl J Med 341:1165-1173, 1999 malignant brain tumors. J Clin Oncol 16:210-221, 1998 11. Grupp SA, Stern JW, Bunin N, et al: Tandem high-dose therapy 27. Gajjar A, Kuhl J, Epelman S, et al: ...
HIV and AIDS is one of the biggest challenges all over the world. There are an approximately 34 million people living with the virus, and a large number of them become infected each year. Although there are some antiviral drugs for HIV viral load reduction, they are not sufficient. There is no cure for AIDS. Nowadays natural resistance or immunity has absorbed attentions. Because in some HIV positive patients progression trend is slow or even they indicate resistance to AIDS. One of the most interesting approaches in this category is CCR5 gene. CCR5 is a main cc-chemokine co-receptor that facilitates HIV-1 entry to macrophage and CD4(+) T cells. To now, many polymorphisms have been known by CCR5 gene that produces a truncated protein with no function. So, HIV-1 could not entry to immune-cells and the body resistant to HIV/AIDS. Delta 32/Delta 32 and m303/m303 homozygotes are example of mutations that could create this resistance mechanism. There is a new treatment, such as Hematopoietic Stem ...
... is distinguished from allogenic stem cell transplantation where the donor and the ... Autologous stem-cell transplantation (also called autogenous, autogeneic, or autogenic stem-cell transplantation and ... is autologous transplantation of stem cells-that is, transplantation in which stem cells (undifferentiated cells from which ... Autologous stem-cell transplantation entry in the public domain NCI Dictionary of Cancer Terms ScienceDaily Report University ...
Bobic V (2000). "Autologous chondrocyte transplantation". Medscape. Retrieved 17 September 2008. "Osteochondritis dissecans of ... "Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation". The New England Journal of ... to 9-year outcome after autologous chondrocyte transplantation of the knee". Clinical Orthopaedics and Related Research. 374 ( ... One such technique is autologous chondrocyte implantation (ACI), which is useful for large, isolated femoral defects in younger ...
Agris J. (1987). "Autologous Fat Transplantation: A Three-year Study". American Journal of Cosmetic Surgery. 4 (2): 95-102. doi ... Bircoll M. Autologous Fat Transplantation (presentation) The Asian Congress of Plastic Surgery, February 1982 Bircoll MJ (1984 ... Asken, S. (1987). "Autologous Fat Transplantation: Micro and Macro Techniques". American Journal of Cosmetic Surgery. 4 (2): ... The long-term, volume maintenance data reported in Breast Augmentation using Pre-expansion and Autologous Fat Transplantation: ...
Autologous bone marrow transplantation is a treatment option. Zanubrutinib is indicated for the treatment of adults with ... Yang L, Wen B, Li H, Yang M, Jin Y, Yang S, Tao J (1999). "Autologous peripheral blood stem cell transplantation for ... Allogeneic stem cell transplantation can induce durable remissions for heavily pre-treated patients. As of October 2010, there ... "Allogeneic Stem-Cell Transplantation in Patients with Waldenstrom Macroglobulinemia: Report from the Lymphoma Working Party of ...
"Autologous Stem Cell Transplantation for Stiff Person Syndrome". JAMA Neurology. 71 (10): 1296-9. doi:10.1001/jamaneurol. ... "Autologous haematopoietic stem cell transplantation for neurological diseases". J Neurol Neurosurg Psychiatry. 89 (2): 147-155 ... Hematopoietic stem cell transplantation (HSCT) with high intensity conditioning protocol has been performed in a few cases with ... There is a limited but encouraging therapeutic experience of hematopoietic stem cell transplantation for SPS. Patients with ...
... autologous hematopoietic stem cell transplantation is sometimes performed. The treatment may induce long-term remission even in ... "Autologous haematopoietic stem cell transplantation for neurological diseases". Journal of Neurology, Neurosurgery, and ...
... and transplantation". Instr Course Lect. 47: 487-504. PMID 9571450. Johnstone B, Yoo JU (1999). "Autologous mesenchymal ... Centeno CJ, Kisiday J, Freeman M, Schultz JR (2006). "Partial regeneration of the human hip via autologous bone marrow ... autologous mesenchymal stem cells, platelet lysate and dexamethasone". Am J Case Rep. 9: CR246-51. Centeno CJ, Schultz JR, ... autologous mesenchymal stem cells" (PDF). Pain Physician. 11 (3): 343-53. PMID 18523506. Centeno CJ, Busse D, Kisiday J, Keohan ...
Autologous hematopoietic stem cell transplantation (HSCT) is sometimes used in severe, treatment-refractory MG. Available data ... Burman J, Tolf A, Hägglund H, Askmark H (February 2018). "Autologous haematopoietic stem cell transplantation for neurological ...
Burman J, Tolf A, Hägglund H, Askmark H (February 2018). "Autologous haematopoietic stem cell transplantation for neurological ...
This is known as autologous stem cell transplantation. Targeted therapy, which first became available in the late 1990s, has ... For this reason, allogeneic HSCT leads to a higher cure rate than autologous transplantation for several cancer types, although ... Allogeneic hematopoietic stem cell transplantation ("bone marrow transplantation" from a genetically non-identical donor) can ... Damodar S, Terunuma H, Sheriff AK, Farzana L, Manjunath S, Senthilkumar R, Shastikumar G, Abraham S. "Autologous Immune ...
Burman J, Tolf A, Hägglund H, Askmark H (February 2018). "Autologous haematopoietic stem cell transplantation for neurological ... "Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica". Neurology. 93 (18): e1732-e1741 ... Hematopoietic stem cell transplantation (HSCT) is sometimes used in severe cases of NMO. Early data suggested that then- ...
Research to investigate if using high‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation was more ... Peinemann F, Enk H, Smith LA (April 2017). "Autologous hematopoietic stem cell transplantation following high-dose chemotherapy ... this is called autologous hematopoietic stem cell transplantation. ...
September 2014). "Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: a ... January 2012). "Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in ... Burman J, Tolf A, Hägglund H, Askmark H (February 2018). "Autologous haematopoietic stem cell transplantation for neurological ... Thomas' hematopoietic cell transplantation: stem cell transplantation. 5th ed. Vol. 2. New Jersey: Wiley-Blackwell; 2016. p. ...
"A Phase I/II trial of edelfosine purging of autologous bone marrow transplantation (ABMT) in acute leukemia (Meeting abstract ... Vogler, WR; Berdel WE (1993). "Autologous bone marrow transplantation with alkyl-lysophospholipid-purged marrow". Journal of ...
January 2003). "Autologous bone-marrow stem-cell transplantation for myocardial regeneration". Lancet. 361 (9351): 45-46. doi: ... Since they come from the patient's own body, this is referred to as an autologous treatment. Autologous remedies are thought to ... Of all stem cell types, autologous harvesting involves the least risk. By definition, autologous cells are obtained from one's ... Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation In National Cancer Institute Fact Sheet web site. ...
"Micro-Autologous Fat Transplantation for Treating a Gummy Smile". Aesthetic Surgery Journal. 38 (9): 925-937. doi:10.1093/asj/ ... and micro-autologous fat transplantation (MAFT). Botox is considered one of the safest and most widely used injectables. Botox ...
Grigg A, Gibson R, Bardy P, Szer J (1996). "Acute portal vein thrombosis after autologous stem cell transplantation". Bone ... As an adjunct therapy with cyclophosphamide for conditioning prior to bone marrow transplantation in adults and children >12 kg ... Pharmacokinetic and dynamic studies support this use, that has prompted its usage in transplantation regimes, particularly in ... in combination with cyclophosphamide or fludarabine/clofarabine as a conditioning agent prior to bone marrow transplantation, ...
The use of autologous grafts prevents transplantation rejection reactions. Grafts used for oral reconstruction are preferably ... Common approaches for replacing damaged oral mucosa are the use of autologous grafts and cultured epithelial sheets. Autologous ... Other than tissue shortage, donor site morbidity is a common problem that may occur when using autologous grafts. When tissue ...
July 2009). "Generation and transplantation of an autologous vascularized bioartificial human tissue". Transplantation. 88 (2 ... This imparts an immunologic benefit similar to autologous cell lines (see above). Autologous cells can be considered syngenic, ... ethics of organ transplantation). The same survey as mentioned above shows on the example of autologous cartilage ... Autologous: The donor and the recipient of the cells are the same individual. Cells are harvested, cultured or stored, and then ...
citation needed] Autologous bone marrow transplantation is currently being investigated.[citation needed] Hepatosplenic ... Treatment solely with doxorubicin can make the disease worse.[citation needed] Allogeneic bone marrow transplantation has been ... "Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma". Blood Cancer Journal. 5 (6): e318. doi: ...
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. N Engl J Med. 2017 Sep 28;377(13):1250-1260. ...
Boggio L, Pooley R, Winter JN (February 2000). "Typhlitis complicating autologous blood stem cell transplantation for breast ...
... hematopoietic cell transplantation stem cell transplantation (4th ed.). Oxford: Wiley-Blackwell. ISBN 9781444303537. Haller M J ... 2008). "Autologous umbilical cord blood infusion for type 1 diabetes". Exp. Hematol. 36 (6): 710-15. doi:10.1016/j.exphem. ... Cord Blood Hematopoietic Cell Transplantation". In Appelbaum, Frederick R.; Forman, Stephen J.; Negrin, Robert S.; Blume, Karl ... "1956: The First Successful Bone Marrow Transplantation". 7 December 2014. Kaiser LR (1992). "The future of ...
... hematopoietic cell transplantation stem cell transplantation (4th ed.). Oxford: Wiley-Blackwell. ISBN 9781444303537. Haller M J ... The EGE concluded that "[t]he legitimacy of commercial cord blood banks for autologous use should be questioned as they sell a ... A woman was reported to have been cured of HIV, the third person ever to be cured of the disease, using a transplantation of ... 2008). "Autologous umbilical cord blood infusion for type 1 diabetes". Exp. Hematol. 36 (6): 710-715. doi:10.1016/j.exphem. ...
October 2009). "Autologous haematopoietic stem-cell transplantation in multiple sclerosis: benefits and risks". Neurological ... In addition, there is a risk of tumorigenesis after stem cell transplantation due to the ability of stem cells to proliferate ... 2020). "Myocardium-targeted transplantation of PHD2 shRNA-modified bone mesenchymal stem cells through ultrasound-targeted ... October 2010). "Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study". Journal ...
December 2006). "Long-term follow-up of autologous peripheral blood stem cell transplantation in the treatment of a patient ... Median survival is about nine months.[citation needed] Autologous stem cell transplantation has been used in treatment. ...
Harel, Adrian (2013-02-13). "Cryopreservation and Cell Banking for Autologous Mesenchymal Stem Cell-Based Therapies". Cell & ... Tissue Transplantation & Therapy. 2013 (5): 1. doi:10.4137/CTTT.S11249. "Cryogenic Storage of Animal Cells". 2010. Retrieved ...
Pacheco F, Oktay K (August 2017). "Current Success and Efficiency of Autologous Ovarian Transplantation: A Meta-Analysis". ...
Autologous stem cell transplantation, using the recipient's own cells, is not curative.: 1458 Younger individuals, if at high ... CLL is treated by chemotherapy, radiation therapy, biological therapy, or bone marrow transplantation. Symptoms are sometimes ... Gribben JG (January 2009). "Stem cell transplantation in chronic lymphocytic leukemia". Biology of Blood and Marrow ... May 2003). "Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for ...
November 15, 2003). "Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma". ... March 2000). "Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy". Journal of Clinical ... 1998). "CD34+CD33- cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients". ... January 25, 2007). False Hope: Bone Marrow Transplantation for Breast Cancer. Oxford University Press. pp. 222-223. ISBN ...
"Autologous Multiple Injections of in Vitro Expanded Autologous Bone Marrow Stem Cells For Cervical Level Spinal Cord Injury - A ... May 2018). "Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ ... October 2006). "Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy". ... September 2011). "Application of autologous bone marrow mononuclear cells in six patients with advanced chronic critical limb ...
Fisher, Andrew (6 June 2018). "Andrew Fisher on Magdi Yacoub: The icon at the heart of UK organ transplantation". British ... a strategy to preserve autologous pulmonary valves". The Journal of Thoracic and Cardiovascular Surgery. 139 (3): 536-542. doi: ... 2004: International Society for Heart and Lung Transplantation Lifetime Achievement Award, at the 24th annual meeting in San ... "The Telegraph - John McCafferty Longest Living Heart Transplantation Survival",, retrieved 9 February 2017 ...
As Director of one of the largest centers for transplantation in Europe, he led a program of heart and lung transplant and ... He also focused his research on a new technique to replace the aortic valve, using autologous pericardium. Results of this ... In 1983, he trained for 6 months at the University of Stanford to specialize in heart and lung transplantation with Professor N ... 2006 First CardioMend autologous pericardial aortic valve reconstruction, Midterm experience with the Jarvik 2000 axial ...
Single Dose Clinical Study to Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-BM-BLD (Autologous cd34+ ...
... or autologous chondrocyte transplantation (ACT). A review evaluating autologous chondrocyte implantation was published in 2010 ... Arumugam, S (2007). "Transplantation of autologous chondrocytes ex-vivo expanded using Thermoreversible Gelation Polymer in a ... Thermann, H; Driessen, A; Becher, C (March 2008). "Autologous chondrocyte transplantation in the treatment of articular ... "Maci" or autologous cultured chondrocytes on porcine collagen membrane, is a treatment to correct cartilage defects in the knee ...
... during high-dose melphalan conditioning reduces oral mucositis after autologous hematopoietic stem cell transplantation". ...
... daratumumab and autologous stem cell transplantation. In 2010, the case of a man with unexplained erythrocytosis and ... "Long-term complete clinical and hematological responses of the TEMPI syndrome after autologous stem cell transplantation". ...
"From stem cells to viable autologous semilunar heart valve". Circulation. 111 (21): 2783-91. doi:10.1161/CIRCULATIONAHA. ... Organ transplantation). ...
... by the deployment of autologous stem cell implantation for repairing the myocardium as an alternative to transplantation, which ... where he performed the first heart transplantation in India on 3 August 1994 and, later, for the first time in Asia, the ...
IL-1α has been administered to patients during receiving autologous bone marrow transplantation. The treatment with 50 ng/kg IL ... α from day zero of autologous bone marrow or stem cells transfer resulted in an earlier recovery of thrombocytopenia compared ...
"Epiretinal Transplantation of Human Bone Marrow Mesenchymal Stem Cells Rescues Retinal and Vision Function in a Rat Model of ... "Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: Phase I study ... "Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: Phase I study ...
... can consider bone marrow transplantation (including stem cell transplantation), which may slow down the progression of the ... The trial was to test the efficacy and safety of autologous (using the patient's own cells) hematopoietic stem cell ... Gene therapy with an autologous stem cell transplant - Italian researchers at the San Raffaele Telethon Institute tested a ... transplantation (HSCT) after genetic modification to deliver a super-therapeutic (over-expressing) ARSA enzyme to the nervous ...
Source material can be normal healthy cells from another donor (heterologous transplantation) or genetically corrected from the ... same patient (autologous). Concerns on patient safety have been raised due to the possibility of contaminating undifferentiated ... cell replacement and transplantation following acute injuries and reconstructive surgery. These applications are limited to the ...
... transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... It may be autologous (the patient's own stem cells are used), allogeneic (the stem cells come from a donor) or syngeneic (from ... Hematopoietic stem cell transplantation remains a dangerous procedure with many possible complications; it is reserved for ... October 1999). "Autologous haematopoietic stem cell transplants for autoimmune disease--feasibility and transplant-related ...
The treatment for JAK3 deficiency is allogeneic hematopoietic stem cell transplantation, which has been demonstrated to be life ... genetic correction and engraftment of autologous hematopoietic stem cells can presume restoring of immunity in JAK3-deficient ... and molecular analyses of 10 patients and outcomes of stem cell transplantation". Blood. 103 (6): 2009-2018. doi:10.1182/blood- ...
This approach, termed autologous bone marrow transplantation, was initially thought to be of benefit to a wide group of ... Autologous transplantation continues to be used as a component of therapy for a number of other hematologic malignancies. The ... However, rigorous studies have failed to confirm this benefit, and autologous transplantation is no longer widely used for ... The proven curative benefits of high doses of chemotherapy afforded by autologous bone marrow rescue are limited to both ...
In children, an autologous bone graft is mostly used. In combination with this transplantation, lipofilling can be used in the ...
Autologous stem-cell transplantation using mesenchymal stem cells (MSCs) has been used to improve recovery time from ACL ...
... and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease". J. Clin. Oncol. 9 (10): 1871- ...
... in repairing the injured heart has led to clinical trials in autologous skeletal myoblast and cardiac stem cell transplantation ... He became the Director of the Heart Transplantation Program before being recruited to the Ohio State University as the Chief, ... Michler completed his residency in General Surgery, a fellowship in Cardiothoracic Transplantation and a residency in ... Division of Cardiothoracic Surgery and Director of the Heart & Lung Transplantation Program. In 2005, Michler returned to New ...
Fat transplantation procedures have been in use for decades to restore volume to the face, and as a result, various techniques ... Facial Autologous Muscular Injection is also known as Fat Autograft Muscular Injection, as Autologous Fat Injection, as Micro- ... Facial autologous muscular injections are procedures that target deep multiplane autologous fat. FAMI consists of an autograft ... Facial autologous muscular injection (FAMI) was developed from 1996 by Roger E. Amar M.D., a French plastic surgeon. Roger Amar ...
The first use of autologous umbilical cord blood cells was done at the Mayo Clinic in 2015 and was found to increase right ... or cardiac transplantation. Current expectations are that 70% of those with HLHS may reach adulthood. Many studies show that ... Phase I trial testing the efficacy of autologous cord blood cell infusion during Stage 1 (Norwood) repair within two-to-three ... APOLLON study is a phase III clinical trial testing the efficacy and safety of intracoronary injections of autologous cardiac ...
In 2006 his team reported on the transplantation of heart valves in two children (11 and 13 years old) done in 2002; the heart ... "Clinical Application of Tissue Engineered Human Heart Valves Using Autologous Progenitor Cells". Circulation. 114 (1 Suppl): I- ... valves originated from donors, were decellularized, and then reseeded with autologous stem cells so that they would continue to ...
By source: Autologous: The donor skin is taken from a different site on the same individual's body (also known as an autograft ... Skin grafting, a type of graft surgery, involves the transplantation of skin. The transplanted tissue is called a skin graft. ... Autologous grafts and some forms of treated allografts can be left on permanently without rejection. Genetically modified pigs ... Ang, G.C. History of skin transplantation. Clin. Dermatol. 2005, 23, 320-324. Scientific American, "Skin Grafting from the Dead ...
Although this approach may be less expensive than traditional surgical transplantation, there is skepticism in regards to ... but also raises questions on the ethical implications of autologous and allogenic sources. More specifically, studies have ... and insures that the artificially formed structure can be broken down upon successful transplantation, to be replaced by a ...
... of combining pembrolizumab immunotherapy with standard chemotherapy drugs and autologous stem cell transplantation (ASCT) in ... A Phase II Study of Pembrolizumab Immunotherapy plus Chemotherapy followed by Autologous Stem Cell Transplantation for ... of combining pembrolizumab immunotherapy with standard chemotherapy drugs and autologous stem cell transplantation (ASCT) in ...
This study demonstrates the potential of autologous BMMNCs intrathecal transplantation in improving the prognosis of functional ... In this study, the effect of intrathecal administration of autologous bone marrow mononuclear cells (BMMNCs) is analyzed on the ... Autologous Bone Marrow Mononuclear Cells Intrathecal Transplantation in Chronic Stroke. Alok Sharma. ,1Hemangi Sane. ,2Nandini ... O. Y. Bang, J. S. Lee, P. H. Lee, and G. Lee, "Autologous mesenchymal stem cell transplantation in stroke patients," Annals of ...
Autologous transplantation of bronchial basal cells. Biological: Bronchial basal cells Autologous transplantation of bronchial ... Autologous Transplantation of Bronchial Basal Cells for Treatment of COPD. The safety and scientific validity of this study is ... Autologous Transplantation of Bronchial Basal Cells for Treatment of Chronic Obstructive Pulmonary Disease (COPD). ... During the process, autologous bronchial basal cells (BBCs) will be dissected from trial tissue from bronchoscopic brushing. ...
Lymphoma survivors who underwent autologous HSCT may be at greater long-term risk for heart failure and left ventricular ... Survivors of lymphoma who underwent autologous hematopoietic stem-cell transplantation (HSCT) may be at greater long-term risk ... Lymphoma Survivors at Greater Risk for Heart Failure After Autologous Transplantation. .social-ris-container { display: flex; ... Lymphoma survivors who underwent autologous HSCT may be at greater long-term risk for heart failure and left ventricular ...
With the premise of improving obesity and its associated disorders, we investigated if fecal microbiota transplantation (FMT), ... heterologous and autologous, potentiates the effects of a moderate caloric restriction (CR) in high-fat diet (HFD)-induced ... Autologous fecal transplantation (FT-A) emerges as a promising strategy to modulate gut microbiota with minimal side effects ... To sum up, we have demonstrated that fecal transplantation and, especially, autologous fecal transplantation, potentiates the ...
Our findings suggest that utility of autologous NIBM-MSCs for cases with poor prognosis after IVDD can be a promising approach. ... Intraspinal Transplantation of Autologous Neurogenically-Induced Bone Marrow-Derived Mesenchymal Stem Cells in the Treatment of ... Each dog received two times a suspension of autologous 5.0x106 NIBM-MSCs, which were positive to CNPase and MAP-2, as well as ... Results: Two months after cell transplantation, there were no changes except for 1 gait score improvement for 1 of the cases. ...
... World J Clin Oncol ... The presumed lack of a graft-versus-tumor effect in autologous stem cell transplantation (ASCT) has been a long-standing ... Autograft mediated adoptive immunotherapy of cancer in the context of autologous stem cell transplantation. World J Clin Oncol ... Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. Bone ...
Transplantation of autologous cells and biomaterials to promote wound healing. *Responsible researcher ... The project investigates novel methods for skin transplantation, with autologous skin cells in combination with biomaterial ...
High-Dose Chemotherapy and Autologous Stem Cell Transplantation Improves Responses in Advanced Follicular Lymphoma ... Autologous Stem Cell Transplantation Improves Responses. High-Dose Chemotherapy and Autologous Stem Cell Transplantation ... According to a recent article published in the journal Blood, high-dose chemotherapy and autologous stem cell transplantation ... These researchers concluded that high-dose chemotherapy with autologous stem cell transplantation is an effective and safe ...
In addition, the prognoses of tandem autologous stem cell transplantation and single autologous stem cell transplantation ... Stem cell transplantation significantly improves prognosis. Autologous peripheral blood stem cell transplantation can ... Thiotepa and melphalan based single, tandem, and triple high dose therapy and autologous stem cell transplantation for high ... Tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma: results of SMC ...
Although there are multiple lines of available therapies and ongoing clinical trials, autologous stem cell transplantation ... Journey of a Patient With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. ... Journey of a Patient With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation ... journeys before and after autologous stem cell transplantation. ... Hematopoietic Stem Cell Transplantation: A Manual for Nursing ...
Copyright © 2022 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health. All rights reserved.. ...
Autologous marrow transplantation for patients with acute myelogenous leukemia--a preliminary report. ... Autologous marrow transplantation for patients with acute myelogenous leukemia--a preliminary report. Journal Article (Journal ... Autologous remission bone marrow transplantation following lethal high-dose chemoradiotherapy results in effective restoration ... during maintenance using high-dose chemoradiotherapy and autologous remission marrow transplantation. Nine patients have ...
Study to compare the impact of immune response in autologous transplantation and allogeneic transplantation. ... There had thus been no studies directly investigating the effect of autologous transplantation and allogeneic transplantation ... Direct Comparison of Autologous and Allogeneic Transplantation of iPSC-Derived Neural Cells in Primate. News Published: October ... Autologous transplantation was found to produce almost no immune reaction and to result in viable neural cells. By contrast, ...
Autologous Stem Cell Transplantation (ACST). Learn the risks and benefits of ACST, a key part of a personalized treatment plan ... Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma. Wednesday, September 22, 2021. 2:00 - 3:00PM ET. View ... This program has a special focus on immunologic therapy in the setting of autologous stem cell transplantation for myeloma. ... and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in ...
Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II ... Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II ... Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis : a phase I/II ... Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis : a phase I/II ...
Autologous osteochondral transplantation (AOT) is a method for articular cartilage repair. However, several disadvantages of ... Autologous osteochondral transplantation (AOT) is a method for articular cartilage repair. However, several disadvantages of ... Autologous osteochondral transplantation (AOT) is a method for articular cartilage repair. However, several disadvantages of ... Autologous osteochondral transplantation (AOT) is a method for articular cartilage repair. However, several disadvantages of ...
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based ... Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based ... Patients with responsive or stable disease after induction treatment, with adequate autologous peripheral blood stem-cell ... randomisation that addresses the efficacy of myeloablative chemotherapy supported by autologous stem-cell transplantation (ASCT ...
"Autologous stem-cell transplantation in patients with HIV-related lymphoma",. abstract = "Purpose: Peripheral-blood autologous ... Autologous stem-cell transplantation in patients with HIV-related lymphoma. Journal of Clinical Oncology. 2009 May 1;27(13): ... Autologous stem-cell transplantation in patients with HIV-related lymphoma. In: Journal of Clinical Oncology. 2009 ; Vol. 27, ... Autologous stem-cell transplantation in patients with HIV-related lymphoma. Pascual Balsalobre, José L. Díez-Martín, Alessandro ...
Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer. 2012 Dec 15; ... Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. In: Cancer. 2012 ; Vol ... Dive into the research topics of Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain ... Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. / Cordes, Stefan; ...
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results ... or intensive chemotherapy and autologous stem-cell transplantation (ASCT) as a first-line treatment of primary CNS lymphoma ( ...
title = "Mast Cell Stabilization Alleviates Acute Lung Injury after Orthotopic Autologous Liver Transplantation in Rats by ... T1 - Mast Cell Stabilization Alleviates Acute Lung Injury after Orthotopic Autologous Liver Transplantation in Rats by ... Mast Cell Stabilization Alleviates Acute Lung Injury after Orthotopic Autologous Liver Transplantation in Rats by ... Mast Cell Stabilization Alleviates Acute Lung Injury after Orthotopic Autologous Liver Transplantation in Rats by ...
AMI patients who received BMC transplantation showed significantly improved cardiac function. BMC transplantation 3-7 days ... BMC transplantation 3-7 days after PCI reduced LV end-diastolic indexes (-4.48; 95% CI, −7.98 to -0.98; P = 0.01) and LV end- ... the decrease was even more remarkable in the LV end-systolic index after BMC transplantation in the group with LVEF ≤ 50% (WMD ... underwent a significant decrease in LV end-diastolic index after BMC transplantation (WMD = -3.29, 95% CI, -4.49 to -2.09; P & ...
In this article, we discuss what autologous HSCT is, which immune-mediated conditions can be treated with it, how to select ... autologous haematopoietic stem cell transplantation (HSCT) is a safe, highly effective and cost-saving treatment modality for ... Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why? ... Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why? ...
Autologous Hematopoietic Stem Cell Transplantation. Myeloablative chemotherapy with immunosuppressive drugs followed by ... autologous transplantation of T cell-depleted hematopoietic stem cells was found to be safe and effective in BD.[104,105] Three ... Autologous HSCT. Stem cell mobilization with CYC (2-4 g/m2) + G-CSF conditioning regimen with melphalan (200 mg/m2). ... Hematopoietic stem cell transplantation; ↑ Increased.. BD: Behçets disease; CYC: Cyclophosphamide; G-CSF: Granulocyte-colony- ...
Kochupillai V, Kumar L, Anandhi R. Autologous bone marrow transplantation. Indian Journal of Pathology & Microbiology. 1991 Apr ...
Effect of autologous epidermal cell suspension transplantation in chronic nonhealing wounds: a pilot study.Can J Surg 2010;53:6 ... Novel approach for chronic wound treatment by autologous transplantation. Viroj Wiwanitkit. CAN J SURG December 01, 2010 53 (6 ... Novel approach for chronic wound treatment by autologous transplantation Message Subject (Your Name) has sent you a message ... Efficacy of autologous transplantation of noncultured epidermal suspension in two different dilutions in the treatment of ...
... infusion of autologous or allogeneic stem cells to reestablish hematopoietic function in patients whose bone marrow or immune ... The image below illustrates an algorithm for typically preferred hematopoietic stem cell transplantation cel... ... Hematopoietic stem cell transplantation (HSCT) involves the intravenous (IV) ... Autologous transplantation. Generally, candidates for autologous transplantation have no demonstrable malignancy in the blood ...
Autologous bone marrow transplantation for acute myeloid leukemia in first remission: Identification of modifiable prognostic ... Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients ... Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. ... Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor- ...
RIST is associated with a higher NRM and lower relapse rate in patients with relapsed FL.Bone Marrow Transplantation advance ... The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed ... The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed ... Bone Marrow Transplantation, 2013, 48, pp.1409-1414. ⟨10.1038/bmt.2013.83⟩. ⟨hal-00849676⟩ ...
  • However, recent reports have shown that the immune effector cells collected at the same time as the stem cells can produce an autologous graft-versus-tumor effect, similar to the graft-versus-tumor effect seen in allogeneic stem cell transplantation without the detrimental effects of graft-versus-host disease. (
  • The presumed lack of a graft-versus-tumor effect in autologous stem cell transplantation (ASCT) has been a long-standing argument against a higher curative potential of ASCT that relies mainly on high dose chemotherapy to eradicate tumor cells, compared with allogeneic stem cell transplantation (Allo-SCT)[ 1 ]. (
  • By contrast, allogeneic transplantation provoked immune reaction by microglia and lymphocytes. (
  • There had thus been no studies directly investigating the effect of autologous transplantation and allogeneic transplantation in primates. (
  • This study by Dr. Takahashi's group sought to clarify this area by transplanting dopaminergic neurons prepared from iPS cells into the brains of cynomolgus monkeys and comparing the extent of immune reaction between autologous and allogeneic transplantation. (
  • The study data show that, in primates, autologous transplantation of iPS cell-derived neural cells produces almost no immune reaction and is superior to allogeneic transplantation in terms of immune reaction control and cell viability. (
  • Cells for HSCT may be obtained from the patient himself or herself (autologous transplant) or from another person, such as a sibling or unrelated donor (allogeneic transplant) or an identical twin (syngeneic transplant). (
  • [ 1 ] More than half of autologous transplantations are performed for multiple myeloma and non-Hodgkin lymphoma , and the vast majority of allogeneic transplants are performed for hematologic and lymphoid cancers. (
  • Worldwide, approximately 90,000 first HSCTs-53% autologous and 47% allogeneic-are performed every year, according to the World Wide Network of Blood and Marrow Transplantation. (
  • We have also found in a number of different studies that the nucleated cell dose significantly affects transplant-related mortality, 1 , 3-5 survival, 1 , 3 and the speed as well as completeness of hematologic reconstitution after autologous 1 , 6 and allogeneic 3-5 transplantation for hematologic malignancies. (
  • The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. (
  • PMR has presented a comprehensive report based on Bone Marrow Transplantation market as per End User (Hospitals, Multispecialty Clinics, and Ambulatory Surgical Centers), Disease Indication (Leukemia, Lymphoma, Myeloma, and Others), Transplant Type (Autologous Bone Marrow Transplant, and Allogeneic Bone Marrow Transplant) based on seven regions. (
  • Studies show that allogeneic stem cell transplantation may benefit patients with high-risk and intermediate-risk AML up to age 75 years and who have an HLA-matched donor. (
  • Allogeneic transplantation uses healthy blood-forming cells from an HLA-matched family member, an unrelated donor, or from umbilical cord blood. (
  • Allogeneic stem cell transplantation, compared to other treatment approaches, is associated with a higher rate of side effects and mortality in patients. (
  • This type of transplantation may be a treatment option for older patients who cannot tolerate the high doses of chemotherapy used in preparation for a standard allogeneic stem cell transplant. (
  • A serious risk of allogeneic and reduced-intensity allogenic stem cell transplantation is graft versus host disease (GVHD) , which develops if the donor's immune cells attack your normal tissue. (
  • Autologous transplants are usually easier for patients to tolerate than allogeneic transplants. (
  • Autologous transplants are used less frequently than allogeneic transplants for AML patients mainly because of the lack of a graft-versus-leukemia effect and the risk of returning some leukemia cells back to the patient. (
  • Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. (
  • Haematopoietic stem cell transplants have been performed in more than 1 500 000 patients (both autologous and allogeneic) to date.1 Although haematological cancers remain the main indication, haematopoietic stem cell transplants are increasingly considered in the treatment of non-malignant disorders and genetic diseases such as haemoglobinopathies (sickle cell anaemia, thalassaemia) that can benefit greatly from this type of transplant. (
  • 7. Is there a role for allogeneic transplantation? (
  • 7. Tandem autologous or allogeneic transplantation was excluded. (
  • Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION . (
  • On a positive note, Medicare will cover cell therapy in two cases: in the instance of Allo-SCT (Allogeneic Stem Cell Transplantation) and Au-SCT(Autologous Stem Cell Transplantation). (
  • ABSTRACT Objective: To assess the domains of quality of life related to hematologic cancer patient health in the first three years from autologous and allogeneic hematopoietic stem cell transplantation. (
  • This resource helps allogeneic and autologous transplant recipients understand and prepare for their post-transplant follow-up care. (
  • Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. (
  • B-cell acute lymphoblastic leukemia developed 5 years after autologous stem cell transplantation for multiple myeloma]. (
  • Autologous stem cell transplantation (ASCT) continues to be the standard treatment for transplant-eligible multiple myeloma (MM) patients. (
  • question, "What is the age limit for autologous stem cell transplantation in patients with Multiple Myeloma? (
  • 2019. High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. . (
  • The purpose of this study is to assess the safety and effectiveness of combining pembrolizumab immunotherapy with standard chemotherapy drugs and autologous stem cell transplantation (ASCT) in patients with Hodgkin lymphoma that has come back or continued to grow despite one regimen of prior therapy. (
  • The infused stem cell autograft in autologous stem cell transplantation (ASCT) has been viewed mainly as hematologic rescue from the myelosuppressive side effect of conditioning regimens. (
  • Here, we report the results of the second randomisation that addresses the efficacy of myeloablative chemotherapy supported by autologous stem-cell transplantation (ASCT), as an alternative to whole-brain radiotherapy (WBRT), as consolidation after high-dose-methotrexate-based chemoimmunotherapy. (
  • Purpose: Peripheral-blood autologous stem-cell transplantation (ASCT) in patients with HIV-related lymphoma (HIV-Ly) has been reported as a safe and useful procedure. (
  • Herein we report the European Group for Blood and Marrow Transplantation experience on patients with HIV-Ly undergoing ASCT. (
  • To determine the efficacy and toxicity of chemoimmunotherapy followed by either whole-brain radiotherapy (WBRT) or intensive chemotherapy and autologous stem-cell transplantation (ASCT) as a first-line treatment of primary CNS lymphoma (PCNSL). (
  • Rituximab-containing induction followed by autologous stem cell transplantation (ASCT) is the standard first-line treatment for young mantle cell lymphoma patients. (
  • We evaluated prognostic factors and treatment outcome of patients with relapsed/refractory Hodgkin's disease (HD) receiving autologous stem cell transplantation (ASCT). (
  • Autologous hematopoietic stem cell transplantation (ASCT) is an increasingly accepted treatment for refractory autoimmune diseases. (
  • Autologous hematopoietic stem cell transplantation (ASCT) is an increasingly accepted effective treatment option for patients with severe autoimmune diseases refractory to conventional treatment 1 and has been used successfully in patients with multiple sclerosis, 2 rheumatoid arthritis, 3 systemic sclerosis, 4 systemic lupus erythematosus, 5 and Crohn disease. (
  • Autologous marrow transplantation for patients with acute myelogenous leukemia--a preliminary report. (
  • Twelve consecutive adult patients with acute myelogenous leukemia have been entered on a treatment protocol which examines the role of 'remission-intensification' during maintenance using high-dose chemoradiotherapy and autologous remission marrow transplantation. (
  • Autologous remission bone marrow transplantation following lethal high-dose chemoradiotherapy results in effective restoration of normal hemopoiesis, is associated with acceptable toxicity and may be an effective means of increasing the numbers of acute leukemia patients having long-term complete remission. (
  • IMSEAR at SEARO: Autologous bone marrow transplantation. (
  • Autologous bone marrow transplantation. (
  • Kochupillai V, Kumar L, Anandhi R. Autologous bone marrow transplantation. (
  • Although variables relating to disease biology and patient characteristics are strong determinants of outcome after bone marrow transplantation (BMT), the identification of these nonmodifiable factors is often of limited practical use. (
  • The current scenario is such that there is an increase in the adoption of Bone Marrow Transplantation procedures for treating various chronic diseases. (
  • This scenario is, by all means, favoring the Bone Marrow Transplantation market growth. (
  • Furthermore, favorable reimbursement policies are also expected to contribute to the growth of the European Bone Marrow Transplantation Market. (
  • Biology of Blood and Marrow Transplantation , 14 (8), 904-912. (
  • Background: Roquinimex is being used for posttransplantation immunotherapy of autologous bone marrow transplantation for acute and chronic myelogenous leukemia. (
  • Bone marrow transplantation , 32 (3), 279-285. (
  • Bone marrow harvested for autologous bone-marrow transplantation may contain residual malignant cells even when it is judged to be in remission. (
  • He has received the 2013 Van Bekkum Award, the most prestigious European Blood and Marrow Transplantation (EBMT) award for the best abstract submitted to the physician''s programme. (
  • He has often been invited to present as Speaker to plenary sessions at international scientific meetings in the fields of MS, neuroimmunology and bone marrow transplantation. (
  • MM is considered an incurable disease despite various methods of treatment, including autologous bone marrow transplantation [3]. (
  • MM is considered relative paucity of CNS invasion by MM an incurable disease despite various meth- in comparison with other tumours, whether ods of treatment, including autologous bone solid or haematological, remain unknown, marrow transplantation [ 3 ]. (
  • The use of filgrastim preparations significantly reduces the frequency and duration of neutropenia in patients after chemotherapy with cytostatics, myeloablative therapy, followed by bone marrow transplantation. (
  • To reduce the duration of neutropenia and its clinical consequences in patients receiving myeloablative therapy with subsequent bone marrow transplantation. (
  • In myelo-ablative therapy followed by bone marrow transplantation, the initial dose of filgrastim - 1 million units (10 μg) per 1 kg of body weight per day - is administered iv drip for 30 min or by continuous iv infusion for 24 hours, or PC. (
  • the first dose is administered no earlier than 24 hours after cytotoxic therapy or bone marrow transplantation. (
  • Be The Match® is a global leader in bone marrow transplantation. (
  • The changes observed after the cell transplantation in the animal studies included increased angiogenesis, increased modulation of neurotrophic growth factors, and reduction in the infarct volumes [ 14 - 20 ]. (
  • Survivors of lymphoma who underwent autologous hematopoietic stem-cell transplantation (HSCT) may be at greater long-term risk for heart failure and left ventricular systolic dysfunction than previously thought, according to the results of a new study conducted by researchers led by Klaus Murbraech, MD, of the department of cardiology at Oslo University Hospital. (
  • Two months after cell transplantation, there were no changes except for 1 gait score improvement for 1 of the cases. (
  • According to a recent article published in the journal Blood , high-dose chemotherapy and autologous stem cell transplantation as initial therapy produces a complete disappearance of cancer in a significant number of patients with advanced follicular lymphoma. (
  • Treatment for follicular lymphoma includes chemotherapy, radiation therapy, stem cell transplantation and/or biologic therapy (treatment used to stimulate the immune system to fight cancer). (
  • Researchers from Italy recently conducted a clinical trial involving 20 medical centers to evaluate the effectiveness and safety of high-dose chemotherapy and autologous stem cell transplantation in 92 patients with previously untreated advanced follicular lymphoma. (
  • These researchers concluded that high-dose chemotherapy with autologous stem cell transplantation is an effective and safe treatment option for patients younger than 60 years with poor prognosis advanced follicular lymphoma, even in facilities that perform few transplants per year. (
  • This study aimed to analyze the efficacy of autologous peripheral blood stem cell transplantation for high-risk neuroblastoma in China. (
  • In addition, the prognoses of tandem autologous stem cell transplantation and single autologous stem cell transplantation groups were compared. (
  • The results of survival analysis showed that autologous peripheral blood stem cell transplantation based on this pretreatment regimen significantly improved the prognosis of children in the high-risk group. (
  • Based on this pretreatment programme, autologous peripheral blood stem cell transplantation is safe and tolerable and significantly improves the prognosis of children in the high-risk group. (
  • The value of tandem autologous stem cell transplantation is worthy of further discussion, which should consider various aspects such as the transplantation medication regimen and the patient's state. (
  • Autologous peripheral blood stem cell transplantation, which attempts to eradicate minimal residual disease with myeloablative chemotherapy and rescue by autologous stem cells (collected from peripheral blood in the previous treatment procedure) to restore bone marrow function, has been included in the standard treatment regimen of high-risk neuroblastoma. (
  • A series of studies on autologous peripheral blood stem cell transplantation have been published, however, these have rarely been conducted in China [ 6 ]. (
  • Since 2010, our centre is the first in China to lead the use of tandem autologous stem cell transplantation for the treatment of high-risk neuroblastoma, the related procedures and conditioning protocols for stem cell collection, storage and reinfusion have been developed and incorporated into the high-risk neuroblastoma standard treatment regimen, known as the Chinese Children's Cancer Group (CCCG) Neuroblastoma (NB)-2015 regimen. (
  • This study, based on 10 years of clinical experience in our centre, retrospectively analyzed the data of high-risk neuroblastomas treated by the CCCG-NB-2015 regimen and summarized the efficacy and safety of autologous peripheral blood stem cell transplantation, including single transplantation and tandem transplantation. (
  • Although there are multiple lines of available therapies and ongoing clinical trials, autologous stem cell transplantation remains the central option for prolonging durations of remission and improving overall survival. (
  • This case study demonstrates how oncology nurses play a critical role in patients' journeys before and after autologous stem cell transplantation. (
  • Hopes have therefore become focused on a therapy with the more radical approach of replacing the lost neural cells through cell transplantation, thereby promoting the formation of new neural pathways to restore brain function. (
  • Background: Autologous non-myeloablative haemopoietic stem cell transplantation is a method to deliver intense immune suppression. (
  • We evaluated the safety and clinical outcome of autologous non-myeloablative haemopoietic stem cell transplantation in patients with relapsing-remitting multiple sclerosis (MS) who had not responded to treatment with interferon beta. (
  • We also sought to investigate the safety and tolerability of autologous non-myeloablative haemopoietic stem cell transplantation. (
  • Interpretation: Non-myeloablative autologous haemopoietic stem cell transplantation in patients with relapsing-remitting MS reverses neurological deficits, but these results need to be confirmed in a randomised trial. (
  • BACKGROUND: The current study was conducted to determine characteristics distinguishing the 10-year survivor group in patients with systemic immunoglobulin light chain (AL) amyloidosis who underwent autologous stem cell transplantation (SCT). (
  • Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why? (
  • In carefully selected patients, autologous haematopoietic stem cell transplantation (HSCT) is a safe, highly effective and cost-saving treatment modality for treatment-resistant, and potentially treatment-naïve, immune-mediated neurological disorders. (
  • 1 Indeed, the autologous cell transplantation is a new approach for medical treatment. (
  • Hematopoietic stem cell transplantation (HSCT) involves the intravenous infusion of hematopoietic stem cells in order to reestablish blood cell production in patients whose bone marrow or immune system is damaged or defective. (
  • For some patients who are in remission and can tolerate intensive chemotherapy, the doctor may recommend stem cell transplantation during the consolidation phase of chemotherapy. (
  • Research to determine which patients are most likely to benefit from stem cell transplantation after their first complete remission is evolving. (
  • This is the most common type of stem cell transplantation used to treat AML. (
  • After treatment with chemotherapy containing alkylating agents and thalidomide, she underwent autologous stem cell transplantation in 2003, with high-dose melphalan as a conditioning regimen. (
  • Among many transplanted cells , adult autologous bone barrow-derived mononuclear cells have beenused in clinical practice because they are easy to be obtained,without immunological rejection and ethical disputationand other advantages.How to distinguish donor cells from receptors and observe the survival of donor cells following stem cell transplantation still trouble people. (
  • Eli Muchtar, MD, Mayo Clinic, Rochester, MN, comments on the results of a study evaluating the feasibility of double autologous stem cell transplantation (autoSCT) in patients with AL amyloidosis. (
  • Some people with rapidly progressive scleroderma may be candidates for autologous hematopoietic stem cell transplantation (HSCT). (
  • Feasibility and safety of autologous bone marrow mononuclear cell transplantation in patients with advanced chronic liver disease. (
  • Bilirubin levels were lower at 1 (2.19 +/- 0.9) and 4 mo (2.10 +/- 1.0) after cell transplantation that baseline levels (2.78 +/- 1.2). (
  • International normalized ratio (INR) decreased from 1.48 (SD = 0.23) to 1.43 (SD = 0.23) one month after cell transplantation. (
  • T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. (
  • The objective of the study was to determine the incidence of invasive fungal disease (IFD) in children undergoing autologous haematopoietic stem cell transplantation (auHSCT) for solid tumours (ST). Retrospective study on auHSCT was performed in children with ST (January 2006-December 2015). (
  • The trial, Autologous Stem Cell Transplantation with CD34-Selected Peripheral Blood Stem Cells (PBSC) in Pediatric and Adult Patients with Severe Crohn's Disease is based on a novel, reduced intensity conditioning regimen, followed by autologous stem cell transplantation. (
  • Regarding the treatment of high-risk patients, autologous stem cell transplantation remains the standard of care in transplant-eligible candidates. (
  • His research programme is aimed at understanding and developing effective therapies for inflammatory neurological diseases, particularly multiple sclerosis (MS). His scientific contributions include studies of T cell repertoires in health and autoimmune disorders, and the elucidation of the mechanisms of action of immuno-modulatory treatments and haematopoietic stem cell transplantation (HSCT) in MS. (
  • Outcomes of corneal transplantation in Europe: report by the European Cornea and Cell Transplantation Registry. (
  • Multicenter double blind trial of autologous bone marrow mononuclear cell transplantation through intracoronary injection post acute myocardium infarction - MiHeart/AMI study. (
  • Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation. (
  • Before their stem cell transplantation, the patient's stool was frozen and reintroduced after the stem cell transplant was stable, with the objective of restoring good bacteria to their gut. (
  • Anticipated to undergo 3 cycles of chemotherapy (solid tumour cancer participants) OR autologous stem cell transplantation (haematological cancers - HSCT participants). (
  • The treatment, autologous haematopoietic stem cell transplantation (aHSCT), has fully halted clinical relapses and the development of new brain lesions in 23 of 24 patients with MS for a prolonged period without the need for ongoing medication. (
  • Combinatorial human progenitor cell transplantation optimizes islet regeneration through secretion of paracrine factors. (
  • Guideline for the Management of Fever and Neutropenia in Pediatric Patients With Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update. (
  • To update a clinical practice guideline (CPG) for the empiric management of fever and neutropenia (FN) in pediatric patients with cancer and hematopoietic cell transplantation recipients. (
  • Lymphoma survivors who underwent autologous HSCT may be at greater long-term risk for heart failure and left ventricular systolic dysfunction than previously thought. (
  • Our findings may help identify lymphoma survivors at increased risk of left ventricular systolic dysfunction after autologous HSCT and can serve as a basis for developing intensified surveillance strategies for these patients," wrote Murbraech and colleagues in the Journal of Clinical Oncology . (
  • Their national cross-sectional study looked at all patients who survived lymphoma and were treated with autologous HSCT in Norway from 1987 to 2008. (
  • In this article, we discuss what autologous HSCT is, which immune-mediated conditions can be treated with it, how to select patients, what are the expected outcomes and potential adverse effects, and how cost-effective this treatment is. (
  • This, along with the development of unrelated cord blood transplantation and familial haploidentical transplantation methods, have improved the likelihood of finding an appropriate HSCT source in a timely manner. (
  • METHODS: The study group included all 74 patients with AL amyloidosis who underwent high-dose melphalan treatment supported by autologous SCT since the beginning of the Mayo Clinic's SCT program until prior to August 2001. (
  • Furthermore, this procedure may be safely performed in clinical centers that perform fewer than 3 autologous stem cell transplants a month. (
  • Moreover, these studies did not involve transplantation of differentiated cells derived from iPS cells in a way that mimicked clinical application. (
  • Several cell-based therapies for adjunctive treatment of acute myocardial infarction have been investigated in multiple clinical trials, but the timing of transplantation remains controversial. (
  • A quantity of basic and clinical studies on transplantation of BMCs in AMI treatment have produced mixed results as the subjects, the approach, the timing and the type and dose of transplanted stem cells varied. (
  • 1 On the other hand, treatment- and transplant-related factors, which are modifiable, can potentially be manipulated in clinical practice to improve the results of transplantation. (
  • This is a clinical investigation of the efficacy of NOVOCART 3D ® Autologous Chondrocyte Transplantation System (Aesculap, Breinigsville, PA) for the treatment of isolated cartilage lesions. (
  • This clinical trial is a new approach to treatment of cartilage lesions with autologous chondrocyte transplantation supplemented with a scaffold. (
  • Pancreatic islet transplantation as a treatment for type 1 diabetes received a major impetus with the development of the Edmonton protocol and recent clinical trials demonstrating long-term insulin independence out beyond 5 years after transplantation ( 1 - 4 ), although encouraging this therapy will always be limited by the relatively small number of organ donors available for islet isolation. (
  • The purpose of this paper is to illustrate the success of autogenous tooth transplantation by means of a clinical case in which the patient underwent transplantation of tooth 38 to the socket of tooth 37, which had been extracted due to extensive decay. (
  • Clinical and experimental studies confirm that tooth transplantation is a safe, rapid and affordable treatment option. (
  • Overall, the research was finalized to implement the clinical application of the autologous cultured epidermis in the treatment of piebald patients. (
  • The National Eye Institute (NEI) seeks research co-development or licensees for making research- or clinical-grade preservation solutions for cold-sensitive organ transplantation or protection of brain injury or trauma during surgery. (
  • With the premise of improving obesity and its associated disorders, we investigated if fecal microbiota transplantation (FMT), heterologous and autologous, potentiates the effects of a moderate caloric restriction (CR) in high-fat diet (HFD)-induced obese mice. (
  • Fecal microbiota transplantation, also known as FMT, is a new way to replenish 'good' bacteria in cancer patients who require stem cell transplants, researchers found. (
  • The process involved using a patient's own stool, known as autologous fecal microbiota transplantation, or auto-FMT for short. (
  • To investigate the efficacy of faecal microbiota transplantation (FMT) in the treatment of IBS. (
  • We postulated that the role of the microbiota in IBS could be clarified by altering the composition of the intestinal microbiota in IBS patients by transplanting them with a complex microbial population, that is faecal microbiota transplantation (FMT). (
  • Seven patients (4 men, 3 women, mean age 61.5 years [range, 51-69 years]) underwent transplantation. (
  • All 7 patients completed the mobilization and leukapheresis procedures successfully and subsequently underwent conditioning and transplantation. (
  • We present a 37-year-old male, with non-cystic fibrosis bronchiectasis underwent bilateral lung transplantation. (
  • METHODS: Ten patients (eight males) with chronic liver disease were enrolled to receive infusion of autologous bone marrow-derived cells. (
  • Therapeutic angiogenesis in patients with systemic sclerosis by autologous transplantation of bone-marrow-derived cells. (
  • The project investigates novel methods for skin transplantation, with autologous skin cells in combination with biomaterial scaffolds. (
  • ②T2+WI showed that 5 of 8 models of myocardial infarction presented fuzzy low-echo signal region in peripheral myocardial infarction after transplantation of labeled cells and the low-echo signal disappeared 4 weeks Iater. (
  • Neonatal porcine islet transplanted NOD-SCID IL2rγ −/− mice received human peripheral blood mononuclear cells (PBMC) with in vitro expanded autologous Treg in the absence or presence of anti-human interleukin-10 (IL-10) monoclonal antibody. (
  • BACKGROUND AND OBJECTIVE: Poor mobilization of peripheral blood stem cells (CD34(+) cells) from bone marrow is a frequent reason for not reaching the autologous stem cell trasplantation (SCT) procedure in patients diagnosed with lymphoma or myeloma. (
  • Forty-nine IBS patients were randomised to receive autologous or allogenic FMT via colonoscopy. (
  • However, the long-term survival of children assigned to the high-risk group is still poor, even under a comprehensive treatment regimen including intensive induction chemotherapy, surgery, radiotherapy, myeloablative chemotherapy with autologous stem cell transplant, and immunotherapy [ 3 - 5 ]. (
  • We hypothesized that upregulation of inflammation triggered by mast cell activation may be involve in ALI after liver transplantation.Methods:Adult male Sprague-Dawley rats received orthotopic autologous liver transplantation (OALT) and were executed 4, 8, 16, and 24 h after OALT. (
  • We determined treatment-related mortality, progression-free survival (PFS), and overall survival (OS) after a second autologous HCT (HCT2) for patients with lymphoma relapse after a prior HCT (HCT1). (
  • Results: We found autologous GVH reactions in three of eight patients (38%) treated with this immunotherapy. (
  • Autogenous tooth transplantations are influenced by pre- and postoperative factors such as the patient's age, stage of root development, type of tooth transplantation, surgical trauma during removal of the transplant, storage after extraction and receptor site. (
  • Researchers have developed a way in which to replenish the low levels of blood cells following high-dose therapy, called an autologous stem cell transplant. (
  • Treatment consisted of intensified induction chemotherapy followed by high-dose chemotherapy and an autologous stem cell transplant. (
  • In this study, the effect of intrathecal administration of autologous bone marrow mononuclear cells (BMMNCs) is analyzed on the recovery process of patients with chronic stroke. (
  • Autologous bone marrow -derived mononuclear cells of minipigs were isolated and cultured. (
  • However, in the groups who received BMC transplantation either within 24 hours or later than 7 days there was no significant effect on treatment outcome. (
  • Treatment of mild hemifacial microsomia in children by autologous nano-fat mixed granule fat transplantation]. (
  • To investigate the effectiveness of autologous nano-fat mixed granule fat transplantation in the treatment of facial soft tissue dysplasia in children with mild hemifacial microsomia (HFM). (
  • The findings from this initial study show that expanded autologous ADSCs may be a promising treatment for T2D. (
  • This report presents, for the first time, the successful treatment of a partial bronchial anastomosis dehiscence complicated by BPF in a bilateral lung transplant patient with autologous platelet-rich plasma (PRP). (
  • The transplantation of human tissues, organs or cells is an established form of treatment that has been acknowledged as the best and very often only life-saving therapy for several serious and life-threatening congenital, inherited and acquired diseases and injuries. (
  • Organ transplantation is often the best, if not the only, treatment for acute and chronic organ failure. (
  • Kidney transplantation is a far more favourable treatment modality versus dialysis in terms of survival, quality of life and cost-effectiveness. (
  • But since autologous PRP (especially in the hands of an experienced dermatologist) is biocompatible with the patient that it was extracted from, there's virtually no risk of the body rejecting the treatment or reacting to it negatively in some way. (
  • In this way we hope to push back the frontier of cord blood transplantation, and make the procedure both safer and available to more patients. (
  • Can we engineer reselected cells to improve migration and engraftment after transplantation? (
  • Autologous MSC transplantation attenuates left ventricular remodeling and improves cardiac performance. (
  • Mesenchymal stem cells are considered an ideal cell source for transplantation. (
  • Islet transplantation have been used to treat DM with some promising results Hirshberg, 2007 . (
  • Adoptive transfer with expanded autologous Treg prevented islet xenograft rejection in human PBMC-reconstituted mice by inhibiting graft infiltration of effector cells and their function. (
  • In vitro Treg expansion was a simple and effective strategy for generating autologous Treg and highlighted a potential adoptive Treg cell therapy to suppress antigraft T-cell responses and reduce the requirement for immunosuppression in islet xenotransplantation. (
  • However, transplantation of reselected ALDHhi cells did lead to a significant increase in islet circumference and total β cell mass, suggestive of direct stimulation of endogenous islet recovery. (
  • Genetic marking and subsequent detection of these cells in recipients would give useful information about the origin of relapse after transplantation. (
  • Although previous recommendations for preventing transmission of human immunodeficiency virus (HIV) through transplantation of human tissue and organs have markedly reduced the risk for this type of transmission, a case of HIV transmission from a screened, antibody-negative donor to several recipients raised questions about the need for additional federal oversight of transplantation of organs and tissues. (
  • In May 2010, the Sixty-third World Health Assembly adopted resolution WHA63.22,1 in which it endorsed the updated WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation and provided strategic directions to support progress in human organ, tissue and cell donation with the aim of maximizing the benefits of transplantation, meeting the needs of recipients, protecting donors and ensuring the dignity of all involved. (
  • Corneal disease (scarring or perforation) can be successfully addressed through transplantation in 80% of affected individuals.3 Tissue transplantation allows many recipients to return to economically productive lives and promotes their independence. (
  • This study demonstrates the potential of autologous BMMNCs intrathecal transplantation in improving the prognosis of functional recovery in chronic stage of stroke. (
  • Shukla and colleagues 1 concluded that "Autologous noncultured epidermal cell suspension transplantation seems to be an effective, simple and time-saving method to treat chronic non-healing wounds. (
  • AIM: To evaluate the safety and feasibility of bone marrow cell (BMC) transplantation in patients with chronic liver disease on the waiting list for liver transplantation. (
  • Our data warrant further studies in order to evaluate the effect of BMC transplantation in patients with advanced chronic liver disease. (
  • The benefits of human tissue transplantation can be seen in both children and adults, including in survival rates following severe burn trauma, recovery of movement, closure of chronic wounds, rehabilitation of heart function and restoration of sight. (
  • For chronic or acute liver failure, as well as some cardiorespiratory conditions, the only alternative to transplantation is death. (
  • Background:Acute lung injury (ALI) is one of the most severe complications after orthotopic liver transplantation. (
  • Our findings suggest that utility of autologous NIBM-MSCs for cases with poor prognosis after IVDD can be a promising approach. (
  • Autologous transplantation is sometimes used for patients who do not have an HLA-matched donor. (
  • The 3-year event-free survival (EFS) and overall survival (OS) rates for the transplantation group and the nontransplantation group were 65.5% vs. 41.3% ( p =0.023) and 77.1% vs. 57.9% ( p =0.03), respectively. (
  • Primary outcomes were progression-free survival and reversal of neurological disability at 3 years post-transplantation. (
  • In contrast, a strong inflammatory reaction often accompanies the release of reactive oxides and other cytokines at the site of infarction after AMI, which is detrimental to the survival and differentiation of autologous myocardial cells and transplanted BMCs [ 6 , 7 ]. (
  • This book also gives the opportunity to learn techniques such as extensive tenectomy, narrow strip conjunctival autograft, sandwich technique, autologous blood, mini-flap technique and minor ipsilateral simple limbal epithelial transplantation (mini-SLET). (
  • Although these therapies can provide some benefit to patients there are limitations, namely the lack of pancreatic islets for transplantation Hirshberg, 2007 McCall and Shapiro, 2012 . (
  • The present report aims to provide a comprehensive analysis of the current situation and facilitate a forward-looking discussion on actions for improving access to transplantation therapies. (
  • However, the detrimental effects of diabetes on progenitor function [2] unfortunately complicates autologous therapies such as this. (